The Energy Code

This is the first dedicated peptide deep dive of The Energy Code — and it starts with arguably the most mitochondrial-centric peptide on the board: SS-31 (Elamipretide). Dr. Mike breaks down a new paper showing how SS-31 may protect neurons in Parkinson’s disease by competing with alpha-synuclein at lipid membranes, slowing toxic aggregation, restoring mitochondrial respiration, and even reducing alpha-synuclein cellular entry. You’ll also hear a key caution: SS-31 appears highly protective at moderate doses, but too much may flip the benefit into harm, reinforcing the “dose makes the medicine” rule in mitochondrial pharmacology. (Educational content only, not medical advice.) - Article Discussed in Episode: Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function - Key Quotes From Dr. Mike: “The future of Parkinson’s therapy may not lie in cleaning up the mess, but rather in providing our neurons with a permanent molecular shield…” “SS-31 acts as a molecular shield protecting the brain’s energy supply…” “SS-31 acts as a molecular bouncer, physically evicting alpha-synuclein from lipid membranes…” “SS-31 substantially prolonged the lag phase of aggregation, essentially stalling the clock on protein buildup.” “These findings underscore the multifaceted protective role of SS-31 against mitochondrial dysfunction caused by alpha synuclein aggregation... SS-31 reversed this decline with a 10 micromolar dose…” - Key Points SS-31 is framed as a mitochondria-first peptide: “restore impaired mitochondrial function” is the headline. Parkinson’s pathology is presented as a cellular power failure inside dopaminergic neurons driven by alpha-synuclein toxicity. SS-31 may act like a “molecular bouncer” — outcompeting alpha-synuclein for anionic lipid membranes and preventing harmful binding/folding. The episode highlights the real-world complication: N-terminal acetylated alpha-synuclein (common in humans) embeds deeper and is harder to displace. SS-31 appears to delay aggregation kinetics (longer “lag phase”) and shift aggregate morphology toward potentially less toxic off-pathway forms. Mitochondrial function was assessed with a Seahorse mito stress test; SS-31 is described as restoring basal/max respiration (at a cited 10 μM dose). Mechanistically, SS-31 is explained as: Cardiolipin binding → supports OXPHOS efficiency/ATP output ROS scavenging (tyrosine residue) → reduces oxidative damage SS-31 may also reduce alpha-synuclein oligomer uptake by altering membrane electrostatics (less negative surface charge). A major warning: very high concentrations (described as 100 μM) may trigger apoptosis / reduce viability. Big-picture: SS-31 supports a “prevention-first” strategy — block the lipid–protein interaction upstream, rather than “cleaning up the mess” later. - Episode timeline 0:00–0:40 — Why peptides are the next major content focus; why SS-31 is the first peptide deep dive 0:40–3:55 — Paper intro + “SS-31 restores impaired mitochondrial function” framing; what the show will cover and why it matters 3:55–5:44 — Parkinson’s as mitochondrial “power failure”; alpha-synuclein as the driver; SS-31 as a BBB-permeable candidate 5:44–6:58 — Takeaway #1: SS-31 as a “molecular bouncer” displacing alpha-synuclein from membranes (dose-dependent) 6:58–8:16 — Takeaway #2: N-terminal acetylation makes alpha-synuclein “stickier” and harder to displace (real-human relevance) 8:16–9:40 — Takeaway #3: Aggregation kinetics + morphology shifts (stalling the “snowball”) 9:40–11:40 — Takeaway #4–#5: Respiration rescue + membrane/cell-entry effects; the dual mechanism (cardiolipin + ROS) 11:40–13:20 — Dose caution, wrap-up, and the “designer peptides” future-forward conclusion - Dr. Mike's #1 recommendations: Deuterium depleted water: Litewater (code: DRMIKE) EMF-mitigating products: Somavedic (code: BIOLIGHT) Blue light blocking glasses: Ra Optics (code: BIOLIGHT) Grounding products: Earthing.com - Stay up-to-date on social media: Dr. Mike Belkowski: Instagram LinkedIn   BioLight Labs:  Website Instagram   BioLight: Website Instagram YouTube Facebook

In this special edition of The Energy Code, Dr. Mike shares a more in-depth discussion on his presentation from Dave Asprey’s BEYOND Biohacking event in Austin: The Energy Code Blueprint: Longevity Starts in the Mitochondria. He introduces BioLight Labs’ initial focus on mitochondrial and longevity peptides, then delivers a thorough foundation on bioenergetics — why “more energy per cell” translates to more vitality, how redox/voltage and electrons relate to inflammation, and why mitochondria act as environmental sensors that drive epigenetics. From there, the episode begins the 6 Pillars of Mitochondrial Wellness, covering Pillar 1 (Energy Production ) —including electron transport chain efficiency and EZ water — and Pillar 2 (Mitogenesis) —with key activators like exercise, fasting, cold exposure, PQQ, urolithin A, and red/near-infrared light. (Educational content only, not medical advice.) - Key Quotes From Dr. Mike: “The more energy you produce per cell, the more vitality you will have... The less energy you produce per cell, the closer to a state of disease you will be.”“Around 80% of modern diseases are directly tied to mitochondrial dysfunction.”“Any wellness strategy that involves harnessing electrons is inherently anti-aging.”“Epigenetics is rooted in the mitochondria. They sense your environment and then send signals to the cell nucelus, which then turns genes on/off based on those mitochondrial signals."“Cardiolipin… is like the bedrock of mitochondrial function... Many researchers now believe cardiolipin deterioration is one of the central hallmarks of mitochondrial aging.”“SS-31’s mission is to fix and repair and prevent damage to cardiolipin. This makes SS-31 the MOST IMPORTANT peptide for mitochondrial function and anti-aging, from the bioenergetic perspective."“After the age of 30, we typically lose about 1% of energy production annually.”“Mitochondrial decline drives the hallmarks of aging... The future is clearly bioenergetic.” - Key Points ⚡️ Longevity is downstream of bioenergetics: more energy produced per cell → more vitality; less energy → disease trajectory. ⚡️ Mitochondria are upstream of symptoms: dysfunction can precede diagnosis by years/decades. ⚡️  “Healing is Voltage”: redox potential, electron availability, pH, and inflammation are tightly linked.

This Deep Dive breaks down a preprint review from Free Radical Biology DR and then goes deeper into the core idea: a “mitoredox shift” (a disruption in mitochondrial redox balance) may be the unifying axis linking oxidative stress to mitochondrial quality-control failure, genome instability, heteroplasmy drift, and regulated cell death. The episode draws a clean line between primary genetic mitochondrial syndromes and far more common secondary mitochondrial dysfunction driven by environmental/metabolic stressors, then explores five big concepts: why redox imbalance collapses mitophagy and mtDNA stability, how “healthy” mitochondria can become hyperactive and accelerate disease, the 60–80% heteroplasmy tipping point, the reperfusion paradox, and emerging frontiers like mitochondrial transplantation, AI-driven oculomics, and new redox-modulating drugs — plus Dr. Mike’s “mitochondrial triad” lens (red light, methylene blue, C60). (Educational content only, not medical advice.) - Article Discussed in Episode: Mitoredox shifts in mitochondrial dysfunction - Key Quotes From Dr. Mike: “Mito-redox shifts… serve as a central link between oxidative stress and various diseases.” “These shifts destabilize essential cellular processes such as mitophagy and mitochondrial DNA stability…” “We are entering an era of mito redox medicine where we manage the electron flow of life itself.” “The retina is the only part of the central nervous system that can be imaged non-invasively… Whereby fluorescence imaging can detect metabolic failures years before physical symptoms appear… that is game changing.” “Life is defined by the steady controlled flow of electrons… when that flow is disrupted… our mitoredox shifts towards mitochondrial dysfunction and, ultimately, disease." - Key Points The review frames mitoredox shifts as a central link between oxidative stress and diverse diseases. Distinguishes primary mitochondrial syndromes (genetic) vs secondary disorders (environmental/metabolic)—with secondary being far more common. Mitoredox shifts destabilize mitophagy + mtDNA stability, leading to dysfunctional organelle buildup and cell death. The shift acts like an upstream master switch, biasing cells toward regulated death programs (e.g., ferroptosis, cuproptosis). “Healthy mitochondria can be hyperactive”: compensatory overwork can spike ROS and accelerate heteroplasmic drift. Heteroplasmy threshold: symptoms often emerge when mutated m

Atrial fibrillation is typically treated like an electrical glitch — rate control, rhythm control, anticoagulation. But this Deep Dive explores a newer frame: AFib may be driven by metabolic collapse and fibrotic remodeling rooted in mitochondrial dysfunction. Dr. Mike breaks down a May 5 Biomedicines paper titled “Humanin and MOTS-c attenuate atrial fibrillation by suppressing fibrosis and mitochondrial dysfunction,” highlighting why mitochondrial-derived peptides (MDPs) — Humanin and MOTS-c — may function as stress-responsive guardians that help preserve mitochondrial integrity, reduce oxidative stress, and blunt fibrosis. You’ll hear the key human tissue findings (both peptides downregulated in AFib atrial appendages), the biomarker signal (plasma MOTS-c inversely tracking NT-proBNP), the “Humanin paradox” (plasma up while atrial tissue down), and the mouse data showing peptide treatment reduced AFib inducibility and structural remodeling. The episode closes with a big question: if heart health is about fueling cellular engines, not just fixing wiring, how does that reshape aging medicine? (Educational content only, not medical advice.) - Article Discussed in Episode: Humanin and MOTS-c Attenuate Atrial Fibrillation by Suppressing Fibrosis and Mitochondrial Dysfunction - Key Quotes From Dr. Mike: “For decades, the medical establishment has approached AFib as an electrical failure…The true culprit may not be the wiring, but rather the power plants.” “In patients with atrial fibrillation, these protective peptides essentially vanish... The more severe the peptide depletion, the more advanced the structural damage appeared to be.” “Our study identifies down regulation of Humanin and MOTS-c as a novel feature of human afib that correlates with fibrosis... As Humanin and MOTS-c levels drop, collagen deposition and atrial fibrosis increase.” “Humanin predominantly influences cell adhesion and immune response pathways, while mots C targets metabolic processes... They effectively attenuated structural remodeling and significantly reduced afib inducibility…” “These micropeptides are born directly within the mitochondrial DNA... They are exercise sensitive myokines, meaning physical activity naturally stimulates their production.” - Key Points The featured paper (May 5, Biomedicines): Humanin + MOTS-c attenuate AFib by suppressing fibrosis and mitochondrial dysfunction. AFib is framed as a growing societal burden and a driver of stroke/heart failure; current therapies mainly manage the “wiring.” Humanin + MOTS-c are mitochondrial-derived peptides

Spinal cord injury is usually framed as a permanent structural problem — axons torn, connections lost, paralysis inevitable. This Deep Dive flips that assumption: the real long-term roadblock may be a secondary mitochondrial energy crisis that turns a helpful early scar into a toxic, permanent barrier. Using a 2026 Frontiers in Neurology review, Dr. Mike and Don unpack how ATP collapse, ROS signaling, failed mitophagy, and mtDNA “false infection” alarmsdrive chronic sterile inflammation, fibrotic hardening, and growth cone collapse. Then they explore the new therapeutic frontier: mitochondria-targeted antioxidants (MitoQ), membrane stabilizers (SS-31), NAD+/AMPK reprogramming, fission/fusion tuning (DRP1/MFN2), mitophagy restoration (PINK1/Parkin, BNIP3/NIX), and even mitochondrial delivery + mtDNA base editing — with the critical caveat: timing matters, because the early scar is initially protective. (Educational content only, not medical advice.) - Article Discussed in Episode: Effect of mitochondrial dysfunction on scar formation after spinal cord injury - Key Quotes From Dr. Mike: “What if the real reason the nerves can’t heal is actually a microscopic energy crisis?” “This entire battle is governed by the powerhouses of our cells, the mitochondria.” “In a severe spinal cord injury, that recycling process… mitophagy… completely fails.” “SS-31… physically binds and stabilizes the cardiolipin… preventing cytochrome C release... It acts like an emergency fuel drop.” “The answer lies in sustained mitochondrial failure.” - Key Points SCI disability isn’t only the “cut” — it’s the secondary metabolic battle that follows. Early glial scar formation is protective: it walls off necrotic tissue and contains inflammation. Acute mitochondrial rupture causes ATP drop + moderate ROS burst that acts as an alarm: ROS → STAT3 activation in astrocytes (glial boundary) ROS → TGF-β1 activation in fibroblasts (ECM deposition) Chronic problem: mitophagy failure leaves fragmented mitochondria leaking mtDNA + excess ROS. Leaked mtDNA looks “bacterial,” driving sterile inflammation via NLRP3 and sustained microglial activation. Chronic inflammatory signaling stabilizes HIF-1α → fibrosis hardens; astrocytes secrete CSPGs that repel axon regrowth. Regenerating axons fail via growth cone collapse from local ATP scarcity + toxic environment. Interventions target the power grid, not just the scar: MitoQ (TPP “VIP pass” into mitochondria) scavenges ROS at the source. SS-31 stabilizes cardiol

What if the next leap in cancer therapy doesn’t come from a billion-dollar lab — but from sea sponges, brown seaweed, fungi, and everyday plants? In this Deep Dive, Dr. Mike and Don unpack a 2025 review on natural compounds that target cancer by attacking mitochondrial metabolism — the tumor’s true center of gravity. You’ll learn how cancer “hotwires” its mitochondria for growth, blocks apoptosis with BCL-2 “bouncers,” and even hijacks mitophagy to survive starvation. Then we break down how compounds like CBD, curcumin, resveratrol, EGCG, fucoidan, and marine/fungal molecules can drain mitochondrial voltage, overload oxidative stress, trigger lethal mitophagy, or cut glutamine supply lines. Finally, we tackle the real bottleneck — delivery — and why conjugates, gold nanoparticles, nanoencapsulation, and synthetic biology may be the bridge from petri-dish magic to real-world oncology. (Educational content only, not medical advice.) - Article Discussed in Episode: Natural compounds targeting mitochondrial metabolism in cancer therapy: a literature review - Key Quotes From Dr. Mike: “Natural compounds… can actually be weaponized against the very unique way a cancer cell feeds itself.” “The tumor massively overproduces those BCL2 bouncers... CBD aggressively drains that battery… the BCL2 bouncers literally lose their grip.” “Curcumin… clogs the exhaust pipes until the factory suffocates on its own fumes.” “Resveratrol… triggers what we call lethal mitophagy.” “EGCG doesn’t just attack the power plant, it cuts off the supply lines entirely.” “Gold nanoparticles are… microscopic armored vehicles... It’s basically a Trojan horse made of gold.” - Key Points Cancer mitochondria aren’t “broken” (Warburg was incomplete) — tumors reprogram mitochondria into biosynthetic superfactories. Tumors rely on fatty acid oxidation and often become glutamine-addicted to feed the TCA “manufacturing hub.” Mitochondria also control apoptosis; cancer survives by overexpressing BCL-2 to block BAX/BAK pore formation and cytochrome c release. Mitophagy is a paradox: early tumor suppression vs. later survival cannibalism under hypoxia/starvation. Natural compounds target key failure points: CBD: drops mitochondrial membrane potential → releases apoptotic blockade. Curcumin: amplifies ROS + mtDNA damage → mitochondrial rupture/apoptosis. Resveratrol: pushes mitophagy into lethal overdrive. EGCG: blocks glutamine utilization (cuts supply lines). Fucoidan: reduces anti-apoptotic defenses across multiple proteins. Marine/fungal agents: uncoupling,

Mitophagy sounds technical — until you realize it may be one of the most important biological processes behind aging, cardiovascular disease, eye degeneration, inflammation, and cellular energy. In this episode, Dr. Mike and Don break down three recent scientific reviews that converge on one central message: when mitochondrial cleanup fails, tissues don’t just lose ATP — they become inflamed, oxidatively stressed, and vulnerable to disease. You’ll learn the difference between autophagy and mitophagy, why damaged mitochondria act like inflammatory “danger beacons,” what this looks like in Fabry disease cardiomyopathy, inflammatory cardiovascular disease, and ophthalmic diseases like glaucoma/AMD/diabetic retinopathy — and why the future of mitochondrial medicine is about restoring the rhythm of removal + renewal. (Educational content only, not medical advice.) - Articles Referenced in Episode:   Mitophagy in ophthalmic pathologies: Molecular mechanisms and therapeutic implications   Understanding Dysfunctional Autophagy and Mitophagy in Inflammatory Cardiovascular Disease   Early mitophagy defects and impaired mitochondrial energy metabolism drive target organ damage progression: lessons from the Fabry heart - Key Quotes From Episode: “Mitophagy… means the body’s process for identifying damaged mitochondria, removing them, and making room for healthier mitochondria to take their place.” “When mitochondrial cleanup fails, the cell doesn’t just lose energy — it becomes inflamed, stressed, and vulnerable to disease.” "Mitochondrial quality control is not a side issue. It may be one of the central mechanisms that determines whether high-demand tissues stay resilient or begin to fail.” “A healthy cell is always asking: which mitochondria are still efficient, and which ones are leaking too much oxidative stress?” “Mitophagy is the process that removes the liabilities.” “Damaged mitochondria are not just weak energy producers. They can actually become inflammatory.” - Key Points Autophagy = general cellular recycling; mitophagy = targeted recycling of damaged mitochondria. Mitochondria are dynamic networks, not static “batteries” — they’re constantly tested, repaired, fused/fissioned, and removed. Damaged mitochondria don’t just make less ATP—they can trigger sterile inflammation by leaking ROS, mtDNA, cardiolipin, etc. Fabry disease heart model: lysosomal dysfunction → impaired mit

What if a fractured wrist didn’t automatically mean weeks of brutal pain — and a medicine cabinet full of NSAIDs or opioids? In this Deep Dive, Dr. Mike and Don break down a 2026 systematic review and meta-analysis (12 randomized controlled trials across 5 countries, ~500 patients) showing that photobiomodulation (red/near-infrared light) can significantly reduce acute fracture pain, improve early upper-limb grip strength, and dramatically reduce sleep-wrecking nocturnal pain — all without reported side effects. You’ll learn why this isn’t “heat therapy,” how mitochondria and cytochrome c oxidase translate photons into biochemical calm, why results are strongest early (and fade later), and what the evidence does not yet prove about speeding true bone knitting on X-ray. (Educational content only, not medical advice.) - Article Discussed in Episode: Effect of photobiomodulation on pain relief and functional improvement in fractures: a systematic review and meta-analysis - Key Quotes From Dr. Mike: “At the 1-week mark… pain scores were significantly lower in the group receiving photobiomodulation.” “At 4 weeks out… grip strength was significantly greater in the light therapy group.” “The risk of experiencing severe sleep-disrupting nocturnal pain was cut exactly in half.” “Photobiomodulation primarily targets the acute inflammatory phase.” “When you irradiate the fracture site directly… you’re acting locally… But laser acupuncture acts systemically.” - Key Points PBM is photochemical, not photothermal — it’s not a heating pad. Mechanism centers on cytochrome c oxidase (mitochondria) → ↑ATP + signaling (NO, Ca²⁺, low “healthy” ROS). Acute pain reduction is strongest at ~1 week vs. sham treatment (VAS/NRS). Nocturnal pain risk cut ~in half (reported risk ratio ~0.49) → major quality-of-life and recovery leverage. Upper-limb fractures: ~+5 kg grip strength improvement around week 4 vs placebo. PBM can work locally (fracture site) and systemically (laser acupuncture points) via neurochemical pain pathways (endorphins, serotonin/norepinephrine, spinal gating/DNIC). Long-term (4–26 weeks): differences in pain/function often wash out as recovery enters remodeling phase. Evidence for faster radiographic bone healing is inconsistent across trials. Energy density window for analgesia looks broad; wavelength matters more (NIR penetrates deeper than red). Big gap: trials largely didn’t measure angiogenesis endpoints, which may matter for longer-term remodeling. - Episode t

Most people think “metabolic treatment” means fewer cravings and a changing number on the scale. This Deep Dive goes microscopic — into the ER–mitochondria contact sites (mito-ERCS) where metabolic dysfunction may begin as a structural failure, not just a hormone problem. Using the paper “GLP-1 receptor and mitochondria contact sites: an emerging mechanism of metabolic regulation,” Dr. Mike and Don explain how chronic metabolic stress can sever a ~20-nanometer communication bridge between the endoplasmic reticulum (cellular “factory”) and mitochondria (cellular “power plant”). Then they explore a provocative idea: GLP-1 receptor agonists may work partly by forming localized “signalosome” hubs at these contact sites — boosting cAMP right where it’s needed — to upregulate MFN2, a tethering “winch” that helps pull fragmented mitochondria back into proper contact and restore calcium/lipid exchange and metabolic flexibility. (Educational content only, not medical advice.) - Article Discussed in Episode: GLP-1 receptor and Mitochondria-ER Contact Sites: an emerging mechanism of metabolic regulation - Key Quotes From Dr. Mike: “The paper introduces a breakthrough concept here called signalosomes.” “GLP-1 receptors physically organize into specialized, highly concentrated hubs… directly at the site of the severed connection.” “Could targeting these microscopic contact sites hold the key to reversing the cellular decay of aging itself?” “When your body enters a state of chronic metabolic dysfunction, the stress acts like a biochemical wrecking ball inside that factory.” “These GLP-1 therapies are far more than just systemic appetite suppressants… They are literal microscopic architects.” - Key Points Metabolic disease may involve physical disruption of ER–mitochondria contact sites (mito-ERCS), not only “slow metabolism” in a vague sense. The paper frames mito-ERCS as a ~20 nm bridge enabling critical ER↔mitochondria communication. Chronic stress is described as triggering an ATF4 → PDE4D → cAMP degradation cascade, contributing to bridge failure. When contact sites fail, mitochondria can fragment, contributing to an “energy crash” phenotype. GLP-1 receptors may assemble into localized signalosomes at mito-ERCS — targeting repair rather than broadcasting diffuse signaling. Local cAMP signaling can promote MFN2 upregulation, helping re-tether mitochondria back to ER at the correct distance. Restored contact sites may normalize calcium and lipid transfer, supporting metabolic flexibility.

This episode of The Energy Code reframes mitochondria from “powerhouses” into master environmental sensors — and explains why mild cellular stress can be the very signal that upgrades your biology. Dr. Mike and Don unpack mitohormesis: the bell-curve logic where too much stress destroys cells, too little causes stagnation, and the “just right” dose triggers repair, resilience, and longer healthspan. You’ll learn how mitochondria “shout” to the nucleus through stress pathways like UPRmt and the Integrated Stress Response (ISR) — including an elegant “fire alarm” cascade (OMA1 → DLE1 cleavage → HRI → eIF2α → ATF4). Then the lens widens from single-cell survival to whole-body adaptation via mitokines like FGF21 and GDF15 (appetite suppression, energy expenditure), plus mitochondrial peptides like MOTS-c. The episode connects this to exercise, fat “browning,” stem-cell hypoxic “seed vaults,” and the darker edge: how cancer hijacks the same survival program to create therapeutic resistance. Finally, it hits the headline takeaway: the future isn’t “eliminate all stress with antioxidants” — it’s precision control of the Goldilocks zone. (Educational content only, not medical advice.) - Articles Referenced in Episode: Mitohormesis Mammalian mitohormesis: from mitochondrial stressors to organismal benefits Mitohormesis; Potential implications in neurodegenerative diseases Mitohormesis and mitochondrial dynamics in the regulation of stem cell fate MITOHORMESIS: THE CORNERSTONE OF THERAPEUTIC RESISTANCE IN CANCER CELLS - Key Quotes From Episode: “Mitohormesis is essentially weightlifting for your cellular engines.” “The very thing causing the damage… is the required key to turn on the system that builds the fire extinguishers.” “Regular physical exercise is, at its core, a mitohormetic stressor.” “If you hit an optimal threshold of mild to moderate mitochondrial stress… it triggers a beneficial, highly active adaptive response.” “We need to start looking at [mitochondria] as the master environmental sensors of the entire human body.” - Key Points Mitohormesis = a nonlinear (bell-curve) response: too much stress → mitochondrial rupture → inflammation → apoptosis too

Sepsis is deadly on its own — but in diabetes, the baseline oxidative stress turns it into a full-blown organ-killing fire. In this Deep Dive, Dr. Mike and Don unpack a new study where water-soluble, hydroxylated fullerene C60 acts like a nanoscale “electron sink,” neutralizing free radicals the way depleted antioxidant enzymes can’t. In a diabetic sepsis model (CLP), C60 sharply reduced lipid peroxidation and protected multiple organ systems — liver, heart, and brain — while also boosting native antioxidant capacity (catalase). The big question: is this just an acute rescue tool… or a future prophylactic “organ armor” strategy? (Educational content only, not medical advice.) - Article Discussed in Episode: Effects of fullerenol C60 on the liver, heart and brain tissues of streptozotocin‑induced diabetic rats with sepsis - Key Quotes From Dr. Mike: "Think of sepsis as a massive fire breaking out in a house… and diabetes like having gasoline already spilled all over the floor." Regarding C60: “It has this amazing capacity to attract and neutralize rogue, unbalanced electrons from free radicals.” “In the liver, there was vastly reduced hepatocyte necrosis.” “In the heart, they saw reduced interstitial fibrosis and way less myocardial disorganization.” “They noted a major decrease in inflammatory cellularity in the brain.” “It’s (C60) not just blocking the fire—it’s like upgrading the body’s sprinkler system.” - Key Points Diabetes pre-loads the system with oxidative stress, making sepsis dramatically more damaging. The model: polymicrobial sepsis via CLP in diabetic rats. “Regular” C60 is insoluble/toxic in biology, but hydroxylated C60 becomes water-soluble and biologically usable. Mechanism frame: C60 as an “aggressive electron sink” that neutralizes free radicals and mimics SOD-like activity. Marker shift: TBARS ↓ (less lipid peroxidation / less membrane damage). Organ protection signals: Liver: necrosis ↓; AST/ALT/GGT/bilirubin ↓ Heart: fibrosis ↓; myocardial disorganization ↓ Brain: inflammatory cellularity ↓ (macrophages, astrocytes) Not just a shield: catalase activity ↑, suggesting support of native defenses. Closing provocation: could daily use in vulnerable populations precondition organs against oxidative storms? - Episode timeline 00:00:19–00:00:52 — Show intro + mission: C60 study + sepsis organ failure in diabetics 00:00:52–00:01:42 — Model setup: diabetic rats + polymicrobial sepsis via CLP</

Mitochondria aren’t just your cell’s power plants — they may also contain a built-in kill switch. In this Deep Dive, Dr. Mike unpacks a 2026 Annual Review of Biophysics paper arguing that ATP synthase (the same machine that makes your ATP) can morph into the mitochondrial permeability transition pore (PT pore) under severe stress — especially calcium overload. You’ll learn the “death finger” model (subunit-e pulling a lipid plug), why cyclophilin D and inorganic phosphate help trigger the switch, and why this matters for real-world tissue injury like stroke and heart attack reperfusion damage. Then comes the twist: brine shrimp (sea monkeys) appear to lack this lethal pore — thanks to a tiny structural tweak that may hint at future strategies to “relax the tension” and keep our cellular dams from blowing. (Educational content only, not medical advice.) - Article Discussed in Episode: The Mitochondrial Permeability Transition Pore: Past, Present, and Future - Key Quotes From Dr. Mike: “For decades, the exact molecular identity of the self-destruct mechanism was a huge mystery in biophysics.” “Your mitochondria actually have exactly that — a built-in kill switch.” “When your mitochondria get overwhelmed by too much calcium, they can open up the permeability transition pore.” “You can picture it as a literal finger hooking into a fatty lipid plug... When there’s a massive overload of calcium, that structural finger just pulls the plug.” “We are basically carrying around a vital energy machine that moonlights as an executioner.” - Key Points The PT pore is framed as a mitochondrial kill switch that opens under extreme stress (notably calcium overload). Modern consensus points toward ATP synthase as the structural basis of the PT pore. “Death finger” model: ATP synthase subunit-e acts like a finger pulling a lipid plug — turning an energy machine into a destructive leak. Cyclophilin D (CypD) behaves like a foreman, helping order the pore to open. Inorganic phosphate is the paradoxical accelerator: despite binding calcium, it changes CypD’s binding behavior, promoting pore opening. Some species (e.g., Artemia franciscana / brine shrimp) appear to lack functional PT pore, tolerating huge calcium loads and hypoxia. Brine shrimp subunit-e has ~15 extra amino acids, creating “slack” that prevents the plug from being pulled. If we can mimic that “relaxed tension,” we may reduce reperfusion injury after stroke/heart attack. - Episode timelin

Emergency medicine is built on brute force — shock the heart, slam vasopressors, crank the numbers. But septic shock exposes the flaw in that instinct: the harder you squeeze vessels from the outside, the more you can starve the microcirculation that actually feeds the kidneys, liver, and lungs. In this Deep Dive, we unpack a 2026 Biomedicine & Pharmacotherapy study testing methylene blue as a precision countermeasure for vasoplegic septic shock. The core mechanism: cytokine-driven iNOS overexpression floods nitric oxide, overactivating the NO → sGC → cGMPrelaxation cascade and collapsing vascular tone. Instead of “chemical duct tape” (high-dose catecholamines), methylene blue blocks the pathway at the source—oxidizing sGC’s heme iron to prevent NO binding and inhibiting further NO production—while also acting as a redox-active electron carrier under oxidative stress. In a CLP sepsis model, 10 mg/kg produced the “Goldilocks” effect: improved MAP, protected lungs and kidneys, reduced IL-1β, boosted antioxidant defenses (SOD, GSH), and lowered lipid peroxidation (MDA). But at 100 mg/kg, the pharmacology flipped—pro-oxidant stress, catastrophic liver injury, and early death. The episode closes with the translational bridge: rat-to-human scaling places the effective dose around ~1.6 mg/kg, aligning with real ICU protocols, while highlighting key limitations (12-hour window, lactate lag, female-only cohort and estrogen effects). (Educational content only, not medical advice.) - Article Discussed in Episode: Dose-dependent effects of methylene blue on hemodynamics, cytokines, oxidative stress, and organ dysfunction in a rat model of CLP-induced sepsis: An experimental study - Key Quotes From Dr. Mike: “In emergency medicine, the instinct is always to overpower the crisis with brute force.” Regarding vasoplegia: "The engine driving it is an overproduction of nitric oxide.” “Methylene blue… oxidizes the heme iron… preventing nitric oxide from binding to sGC.” “It (methylene blue) restores normal vascular tone without aggressively squeezing the vessel from the outside.” “At super-therapeutic concentrations, methylene blue stops acting as an efficient electron carrier... Instead of smoothly passing electrons… it begins indiscriminately stealing electrons and auto-oxidizing.” “That is the inherent danger of redox-active compounds.” - Key Points Septic shock punishes “brute force” care: raising MAP can collapse microvascular perfusion and accelerate organ failure. Core driver of vasoplegia: iNOS → excess NO → sGC activation → cGMP surge → v

What if the spinach in your salad, the berries in your smoothie, and the caffeine in your coffee aren’t “fuel” at all — but evolved plant defense chemicals that can directly modify your mitochondria? In this deep dive, we unpack a 2025 paper from the International Journal of Molecular Sciences (“Plant Secondary Metabolites as Modulators of Mitochondrial Health”) and follow the mechanisms step-by-step: how mitochondria maintain themselves through biogenesis, fusion/fission, and mitophagy; how compounds like berberine can trigger a controlled “fake energy crisis” to induce cleanup + rebuilding; how caffeine can interrupt apoptosis signaling under UV stress; why astaxanthin can reducemitophagy during acute oxidative panic to prevent cellular self-cannibalism; and why some “plant” benefits (like urolithin A) depend entirely on your gut microbiome. Finally, we hit the paradox: these same metabolites can become selectively cytotoxic to cancer cells—or become dangerous when isolated into high-dose supplements, with real toxicity and drug-interaction risk. The takeaway: food isn’t just calories — it’s environmental code. (Educational content only, not medical advice.) - Article Discussed in Episode: Plant Secondary Metabolites as Modulators of Mitochondrial Health: An Overview of Their Anti-Oxidant, Anti-Apoptotic, and Mitophagic Mechanisms - Key Quotes From Dr. Mike: “The spinach in your salad… the berries in your smoothie… and even the caffeine in your morning coffee were actually highly evolved chemical weapons.” “We really have to stop thinking of plants just as vitamins and start looking at them as complex chemical defense systems.” “Berberine… creates a fake crisis to force an upgrade.” “Caffeine… effectively jams the self-destruct button.” “Think of the plant compounds you consume as environmental software updates.” - Key Points Mitochondria aren’t static batteries — they’re a dynamic fleet: biogenesis, fusion, fission, mitophagy. Mitophagy failure → exhaust (ROS), DNA damage, and programmed cell death pathways that show up in chronic disease. Plant secondary metabolites evolved as defense chemistry — but “keys fit locks” due to shared ancient biochemical language. Berberine: induces a mild energy dip → triggers mitophagy + biogenesis (cleanup + upgrade loop). Caffeine: can intercept UV-stress death signaling, helping cells survive and repair rather than self-destruct. Astaxanthin: can stabilize membranes and dial back runaway mitophagy during acute oxidative crises. Urolithin A: you can’t “eat

Photobiomodulation therapy (PBMT) is marketed like universal biology: shine the right wavelength, hit cytochrome c oxidase, boost ATP, accelerate healing. But this Deep Dive unpacks a hidden variable that can make “standard dosing” either ineffective or unsafe: melanin. Using a 2026 narrative review from researchers at the University of São Paulo, we trace the physics of a photon entering the body, how melanin’s absorption overlaps the therapeutic “optical window,” and why simply “turning up the laser” can backfire — creating heat and reactive species in the epidermis while deeper target tissues get little benefit. We also confront a data problem: trials may include darker phototypes, but too often outcomes aren’t analyzed by skin type, creating a misleading “average” that masks risk. Finally, we outline practical fixes — wavelength selection, spot size adjustments, and pigmentation-sensitive, feedback-guided dosimetry — so PBMT can become truly personalized and equitable. (Educational content only, not medical advice.) - Article Discussed in Episode: Is photobiomodulation therapy free from racial bias?: a narrative review of skin pigmentation - Key Quotes From Dr. Mike: Regarding melanin: “It literally absorbs the photons before they can ever reach the deeper tissues.” “For individuals with darker skin tones, this can result in totally subtherapeutic treatments.” “They currently do not differentiate dosing parameters based on skin pigmentation.” “The physics of a photon is constant. But the biological filter it’s passing through is wildly diverse.” “At 660 nm… 21 mm in lighter skin… but in darker skin it drops to 14 mm.” “We need to stop treating light therapy like a one-size-fits-all t-shirt… and treat it like a custom tailored suit.” - Key Points PBMT’s core mechanism: photons → mitochondrial chromophores (cytochrome c oxidase) → ATP support and healing. The optical window (≈600–1100 nm) overlaps with melanin’s strong absorption (≈600–900 nm). Darker skin = more melanin absorption, meaning less light reaches deeper tissue → risk of subtherapeutic dosing. “Just increase power” can be dangerous: melanin absorbs more energy → heat + ROS/RNS → redness, pain, burns. Guideline gap: WALT dosing recommendations don’t meaningfully adjust for pigmentation. Data aggregation problem: studies include darker phototypes but often don’t stratify outcomes, producing “average” conclusions that can hide harm. Fixes the paper argues for: longer wavelengths (e.g., 830–1064 nm), larger spot sizes, gradual ramping + patient sensor

Upon Don Bailey's return to the Deep Dive episodes, he and Dr. Mike reframe fatigue, aging, and neurodegeneration through one core process: mitophagy — the cell’s highly selective mitochondrial recycling program. The episode starts with a hard truth: “engineering-style” diagnoses feel comforting, but chronic fatigue and cognitive decline live in a murky zone standard tests rarely capture. From there, the conversation builds a vivid model of mitochondrial energy production (OXPHOS), the unavoidable “exhaust” of ROS, and the multi-tiered quality control stack that keeps your cellular power grid from collapsing: biogenesis (PGC-1α), dynamics (fusion/fission), and mitophagy (the scrapyard). Then it goes deeper — showing how mitophagy failure can turn mitochondrial damage into neuroinflammation (via leaked bacterial-like mtDNA and the NLRP3 inflammasome) and even “cellular rust” (ferroptosis) when iron-driven lipid peroxidation spirals out of control. The episode also tackles the paradox: mitophagy is protective — until extreme stress pushes it into overdrive, potentially tipping into ferroptosis. Finally, it translates the research into real levers: exercise as hormetic signaling (MICT vs HIIT), the AMPK↔mTOR seesaw, and biohacking tools like urolithin A, spermidine, resveratrol, and adaptogens — not as exercise replacements, but as precision amplifiers that help you stay in the “Goldilocks zone.” (Educational content only, not medical advice.) - References From Episode: Mechanistic Modulation of Autophagy by Bioactive Natural Products: Implications for Human Aging and Longevity Early mitophagy activation by Urolithin A prevents, but late activation does not reverse, age-related cognitive impairment Mitophagy as a therapeutic target for exercise-induced fatigue: modulation by natural compounds and mechanistic insights Mitophagy in Alzheimer’s disease and its potential as a therapeutic target - Key Quotes From Episode: “Mitophagy is the scrapyard.” “If the trash isn’t being collected, your cells become crowded with clunker mitochondria.” “We are fundamentally as young as our mitochondrial recycling program.” Regarding Urolithin A: “The supplement isn’t a replacement for the gym. It’s an amplifier.” “You cannot supplement your way out of a sedentary l

In this Energy Code Deep Dive episode, Dr. Mike breaks down a modern (and slightly unsettling) obesity paper: blue light exposure worsened obesity in high-fat diet–fed mice — not just through “sleep/circadian disruption” in the abstract, but via signals consistent with mitochondrial dysfunction and oxidative stress in subcutaneous white fat. The study compares normal vs high-fat diet mice under white light vs blue light and finds that blue light, in the high-fat context, is associated with more weight/fat gain, worse glucose handling, lower whole-body energy expenditure, and a strong tissue-specific signal in inguinal white adipose tissue (iWAT) — a depot closer to the surface that may be more vulnerable to light penetration. Mechanistically, the paper points toward suppressed oxidative phosphorylation gene expression plus higher ROS/lipid peroxidation and weaker antioxidant defenses in iWAT. The key takeaway: in a high-fat environment, blue light may act like a metabolic amplifier — increasing load while weakening the machinery that should burn fuel cleanly. (Educational content only, not medical advice.) - Article Discussed in Episode: Blue light exposure exacerbates obesity in high-fat diet-fed mice by inducing mitochondrial dysfunction in the white adipose tissue - Key Quotes From Dr. Mike: “Blue light, obesity, fat tissue, and mitochondrial dysfunction… modern and a little unsettling.” “Could the kind of light we are increasingly surrounded by actually make metabolic dysfunction worse… by directly damaging the way fat tissue handles energy?” “In mice eating a high-fat diet, blue light exposure led to more weight gain and more body fat than white light exposure.” “Blue light exposed high-fat mice had lower oxygen consumption, lower carbon dioxide production, and lower heat production.” “Light is not just visual information, it is metabolic information.” - Key Points The paper asks: can blue light worsen obesity beyond circadian/sleep effects — via fat-tissue mitochondria? 4 groups: normal diet vs high-fat diet × white light vs blue light exposure. In high-fat diet mice, blue light → more weight gain + more body fat than white light. Blue light + high-fat diet → worse glucose tolerance and insulin sensitivity. Strongest depot effect: inguinal white adipose tissue (iWAT) (subcutaneous, closer to surface). Visceral depot (e.g., epididymal WAT) showed less pronounced change, supporting “location matters.” Whole-body physiology: blue light high-fat mice had lower O₂ consumption, CO₂ producti

In this Energy Code Deep Dive episode, Dr. Mike unpacks a paper that reframes ALS at a deeper level: ALS may begin as an energy regulation failure, starting in the hypothalamus, before it becomes an obvious motor neuron story.The hypothalamus isn’t just “another brain region”; it’s the body’s metabolic control room — governing hunger, energy expenditure, hormones, and fuel signaling. The paper shows that in ALS mouse models, the hypothalamus develops early mitochondrial bioenergetic impairment (including reduced spare respiratory capacity) alongside neuroimmune activation (astrocytes and microglia) and melanocortin circuit disruption (POMC/AgRP imbalance) that could help explain early hypermetabolism and weight loss seen in ALS. Most provocatively, early metabolic modulation (TMZ) restored hypothalamic bioenergetics, reduced glial activation, normalized aspects of circuit signaling, delayed onset, and extended survival — suggesting the “first domino” may be a failing energy command center, not just downstream motor collapse. (Educational content only, not medical advice.) - Article Discussed in Episode: The hypothalamus is an early site of mitochondrial failure and neuro-immune circuit disruption in amyotrophic lateral sclerosis - Key Quotes From Dr. Mike: “ALS may not begin only as a motor neuron story. It may also begin as an energy regulation story.” “Mitochondrial dysfunction shows up in the hypothalamus before symptoms begin.” “If that is true, then ALS is not just a disease of movement. It is also a disease of failed energy coordination.” “These hypothalamic mitochondrial changes… happened before major motor symptoms.” “…if you intervene early at the level of hypothalamic energy failure, you may be able to change the trajectory of disease.” - Key Points ALS may not start only in motor neurons; it may start with hypothalamic energy-control failure. The hypothalamus is the body’s metabolic thermostat/control room (hunger, weight, hormones, energy use). Hypermetabolism + weight loss are common in ALS and correlate with worse outcomes — this may be upstream, not just secondary. In ALS models, hypothalamus shows early mitochondrial dysfunction before symptom onset. Key mitochondrial finding: reduced maximal respiration + reduced spare respiratory capacity (“backup power” loss). Changes are region-specific: hypothalamus shows the strongest coordinated mitochondrial/inflammatory signature vs hippocampus/cerebellum. Early astrocyte and microglia activation appears alongside metabolic reprogramming toward glycolysis. Melano

In this Energy Code Deep Dive episode, Dr. Mike breaks down a provocative neuroprotection review: low-dose methylene blue and near-infrared (NIR) light may look like totally different therapies — one is a molecule, one is photons — but the paper argues they converge on the same core target: mitochondrial respiration. You’ll hear a simple “neurons as cities / mitochondria as power plants” model for neurodegeneration, why methylene blue can function like an alternate electron shuttle in the electron transport chain, how NIR light can energize cytochrome oxidase, and why both approaches may widen the neuron’s “energy margin” during stress. The takeaway isn’t “magic cures.” It’s a disciplined mitochondrial lens: improving the power supply may give repair, plasticity, and survival systems the bandwidth to work. (Educational content only, not medical advice.) - Article Discussed in Episode: Protection against neurodegeneration with low-dose methylene blue and near-infrared light - Key Quotes From Dr. Mike: “Two very different therapies (methylene blue higher dose can backfire). Near-infrared light: photons absorbed by cytochrome oxidase → boosts mitochondrial respiration and ATP. NIR effects may outlast a session via enzyme induction / capacity signaling (not just a short “boost”). Unifying mechanism: both interventions enhance oxidative metabolism and support neuronal survival under stress. Paper reviews multiple model contexts (ischemia, trauma, neurotoxicity, neurodegeneration models, etc.) as “shared bottleneck” evidence. Prac

In this Energy Code Deep Dive episode, Dr. Mike breaks down a practical 8-week human study on shilajit and performance where it actually matters: after fatigue sets in. Recreationally active young men took placebo, 250 mg/day, or 500 mg/day, then got pushed through a brutal leg-extension fatigue protocol to see how much strength they lost — not just how strong they were fresh. The standout finding: in the stronger half of subjects, the 500 mg group preserved significantly more maximal isometric strength post-fatigue — and showed a quieter signal on serum hydroxyproline, a marker often used to reflect collagen/connective-tissue turnover. Bottom line: this paper doesn’t claim “instant strength.” It suggests shilajit may be more interesting as a fatigue-resistance + tissue-support tool — at the right dose, in the right population. (Educational content only, not medical advice.) - Article Discussed in Episode: The effects of Shilajit supplementation on fatigue-induced decreases in muscular strength and serum hydroxyproline levels - Key Quotes From Dr. Mike: “In that stronger subgroup, the high dose shilait group lost significantly less maximal isometric strength after the fatiguing protocol…” “So in simple terms, the men taking 500 mg per day of Sheelajit held on to their strength better once fatigue hit.” “This was not a study showing Shilait magically blocks exercise damage… It is more a study suggesting that over time, the higher dose may support the tissue environment…” “The strongest and cleanest finding is this… 500 mg per day… helped preserve maximal strength better after fatigue…” “Sometimes performance support is not about creating more force at the start. Sometimes it is about losing less force when fatigue tries to take it away.” - Key Points The study asks a real-world question: how much strength do you lose when you’re tired? Design: recreationally active young men; placebo vs 250 mg/day vs 500 mg/day for 8 weeks. Test: maximal isometric strength pre-fatigue, then 2×50 maximal concentric isokinetic leg extensions, then post-fatigue testing. Primary performance signal showed up in the upper 50% (stronger subjects): 500 mg/day = less post-fatigue strength loss. The lower dose (250 mg/day) did not clearly separate from placebo in that stronger subgroup. Hydroxyproline (HYP) was used as an indirect marker of colla

Dr. Mike unveils BioShilajit — a “trio stack” built for mitochondrial performance: shilajit for ionic minerals + fulvic/humic support, PQQ to signal mitochondrial biogenesis (PGC-1α), and pharmaceutical-grade methylene blue as a low-dose electron-cycling “failsafe” for the respiratory chain. Along the way, he breaks down why chronic fatigue and brain fog often evade standard labs, walks through the origin story and chemistry of shilajit, highlights ATP and endurance data, explains PQQ’s unique role in building new “cellular engines,” and tells the bizarre history of methylene blue — from textile dye to essential emergency medicine — before tying it all together as structure + supply + backup mechanics for cellular energy. He closes with launch details, the first-week discount code, and where to find the full resource library on the BioLight product page. (Educational content only, not medical advice.) - Article Discussed in Episode: Fullerenes as Anti-Aging Antioxidants - Key Quotes From Dr. Mike: Regarding BioShilajit: "A mountain resin, a bacterium, and a clothing dye… sounds like quite the trio.” “Shilajit roughly translates to: the conqueror of mountains and destroyer of weakness.” “Shilajit contains over 85 distinct trace minerals — and the key word is bioavailable.” “Shilajit is the pharmacological opposite of a stimulant — it doesn’t tape over the check-engine light; it helps the cell produce more of its own ATP.” “A microscopic picomolar concentration of PQQ can execute thousands — sometimes tens of thousands — of redox cycles without breaking down.” “PQQ triggers this exact same genetic alarm bell (PGC-1α -> mitogenesis) — but without the ten-mile run.” “Inside damaged mitochondria, methylene blue’s mechanism is bypassing the blockade (blockages in the ETC).” - Key Points Two BioLight events + one roadmap: Beyond Conference (Austin, May 27–29), Return to Nature (Franklin, June 11–12), and a tentative A4M plan (December). Core thesis: chronic fatigue/brain fog often reflects micro-level mitochondrial “power grid” failure, not a single broken marker on standard labs. BioShilajit = “unlikely trio”: shilajit + PQQ + methylene blue designed as a closed-loop energy system. Shilajit basics: paleo-humus resin rich in fulvic/humic acids, DBP-like compounds, and ionic trace minerals for high absorption. ATP angle: shilajit framed as ATP preservation + ETC enzyme protection under stress (mouse forced-swim model described). Stimulant vs metabolic: shilajit positioned as the opposite of “masking fatigue” (caffeine analogy). PQQ: framed as

What if one of the strangest molecules in biology — the carbon “nanoball” known as C60 — could meaningfully influence aging? In this Energy Code Deep Dive, Dr. Mike breaks down the paper “Fullerenes as Anti-Aging Antioxidants” and explores why fullerenes have become a lightning-rod topic in longevity. You’ll learn what fullerenes are, why their electron-handling chemistry makes them different from typical antioxidants, and how the review frames their potential role in oxidative stress and mitochondrial function. We unpack the famous C60-in-olive-oil lifespan study, the proposed mechanisms (from “radical sponge” behavior to a more strategic mitochondrial ROS-reduction hypothesis), and the most important caveat: context and formulation can flip the biology. Preparation, dose, impurities, and even light exposure can shift fullerenes from promising to problematic—so this episode is about the science, the signal, and the safety questions that still need answers. (Educational content only, not medical advice.) - Article Discussed in Episode: Fullerenes as Anti-Aging Antioxidants - Key Quotes From Dr. Mike: “These molecules (Carbon 60) can accept electrons… interact with free radicals… and move through lipid membranes.” “ROS are like sparks coming off a machine… a few sparks are normal, too many sparks start causing damage.” “Fullerenes can accumulate in mitochondria… placing a fire extinguisher inside the power plant itself.” “Now the fullerene is not just cleaning up sparks after they happen, it may be reducing how many sparks the mitochondrial power plant throws off in the first place.” “Sometimes the most interesting ideas in anti-aging science are not the ones that sound familiar.” - Key Points What fullerenes are: spherical carbon cages; C60 = 60 carbon atoms in a “soccer-ball” structure. Why the hype exists: they can accept electrons, interact with free radicals, and move through lipid membranes. Aging framework: ties into the free radical/mitochondrial oxidative stress model of aging. The headline animal finding: C60 dissolved in olive oil was associated with a large lifespan increase in rats (not a human claim). How they may work: not only scavenging ROS, but possibly triggering protective pathways. Mitochondria angle: evidence suggests mitochondrial accumulation, potentially changing ROS “at the source.” Provocative mechanism hypothesis: fullerenes may behave like a mi

In this Deep Dive episode, Dr. Mike breaks down a landmark first-in-human study on urolithin A — one of the most important translational steps yet in mitochondrial longevity science. The paper asks the question the field has been waiting for: when you target mitophagy (the selective cleanup of damaged mitochondria) in real humans, does it appear safe, does it reach the bloodstream and tissue, and does it actually shift biology in the direction of healthier mitochondrial function? You’ll learn why urolithin A is different from typical “mitochondria boosters,” how the study tested safety, tolerability, and bioavailability, and why it matters that urolithin A was detected in skeletal muscle. Dr. Mike also explains the key biomarker signals—like reductions in plasma acylcarnitines — and the muscle gene-expression changes that suggest a coordinated mitochondrial health signature, including comparisons to patterns seen in healthier, more active older adults. The takeaway: this study doesn’t prove performance gains yet — but it strongly supports that mitochondrial quality control is a targetable human biology, and it opens the door for larger efficacy trials. (Educational content only, not medical advice.) - Article Discussed in Episode: The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans - Key Quotes From Dr. Mike: “Aging is also the progressive failure of mitochondrial quality control.” “Instead of just trying to stimulate mitochondria harder… (with urolithin A) you are trying to improve the quality of the mitochondrial population itself.” “Urolithin A was detectable in skeletal muscle after oral dosing…” “This is not just a paper saying urolithin A is present in blood… the muscle is responding with a transcriptional program consistent with improved mitochondrial health.” “The molecular signature induced by urolithin A resembles aspects of what is seen with regular exercise.” - Key Points Why it matters: A “mitophagy-first” intervention is tested in humans, not just cells or animals. Study design: Randomized, double-blind, placebo-controlled Phase 1 in healthy sedentary older adults, with single- and multiple-ascending dose arms (28 days). Safety: Favorable profile, no serious adverse events reported; no major lab/ECG concerns noted in the transcript. Bioavailability: Detectable in plasma across doses; dose-dependent exposure from 250–1000 mg. T

In this Energy Code Deep Dive, Dr. Mike unpacks Mitochondria at the Heart of Aging: Structure, Function, and Failure — a sweeping review arguing that aging isn’t just random damage over time, but a progressive loss of mitochondrial adaptability. The episode walks through the core failure loops that accelerate aging across tissues: mtDNA instability → impaired oxidative phosphorylation → rising ROS → more mtDNA damage, plus breakdowns in fusion/fission architecture, mitophagy and quality control, NAD⁺ metabolism and sirtuin resilience, and the inflammatory spillover that turns mitochondrial stress into inflammaging. The key takeaway: mitochondria aren’t background “powerhouses” — they’re a systems-level coordinator of redox, metabolism, cleanup, and stress responses, and aging may be the gradual loss of that mitochondrial “intelligence.” (Educational content only, not medical advice.) - Article Discussed in Episode: Mitochondria at the heart of aging: structure, function, and failure - Key Quotes From Dr. Mike: “Aging is not just reducing mitochondrial quantity, it is degrading mitochondrial architecture.” “Mitochondrial aging is a network problem, not a single molecule problem.” “Aging is in part the loss of mitochondrial intelligence.” “Not all tissues age the same way mitochondrially.” “We are not just trying to stimulate energy. We are trying to restore mitochondrial adaptability.” - Key Points Central thesis: Aging = loss of mitochondrial adaptability, not just lower ATP. Mitochondria as aging hub: redox control, apoptosis, inflammation coordination, metabolic flexibility, QC. Hallmarks link: mitochondrial dysfunction interacts with genomic instability, senescence, inflammaging, proteostasis loss, stem cell exhaustion. mtDNA vicious cycle: mtDNA mutations/deletions → weaker OXPHOS → more ROS → more mtDNA damage. Tissue vulnerability: post-mitotic, high-demand tissues (brain, heart, skeletal muscle) are hit hardest. Dynamics failure: imbalance in fusion (MFN1/2, OPA1) and fission (DRP1) → fragmentation + crista disruption + reduced stress tolerance. Mitophagy decline: PINK1/Parkin + BNIP3/NIX/FUNDC1 pathways weaken → damaged mitochondria accumulate. Inflammaging bridge: mtDNA/ROS/cardiolipin danger signals activate cGAS–STING and NLRP3. NAD⁺ collapse loop: NAD⁺ decline → weaker SIRT1/SIRT3 → lower resi

In this Energy Code Deep Dive, Dr. Mike breaks down a preclinical paper testing methylene blue in a classic ovalbumin (OVA)–induced allergic asthma mouse model. The core question: if allergic asthma is driven by a self-reinforcing loop of TH2 cytokines (IL-4, IL-13), IgE signaling, eosinophilic airway infiltration, and oxidative stress, can a redox-active compound interrupt the cycle? The study reports dose-dependent improvements across airway inflammation (BALF immune cells), immune programming (IL-4/IL-13 + OVA-specific IgE), oxidative damage (MDA), antioxidant defenses (GSH/GPx), and lung histology — while emphasizing the key caveat: this is not human clinical asthma, and safety/translation questions remain open. (Educational content only, not medical advice.) - Article Discussed in Episode: Methylene blue attenuates ovalbumin-induced airway inflammation and oxidative stress in mouse model of asthma - Key Quotes From Dr. Mike: “Oxidative stress is not a side issue in asthma, it is part of the disease mechanism.” “Eosinophilia is one of the hallmarks of allergic asthma.” “Methylene blue significantly reduced those IgE levels… in a dose-dependent manner.” “Both cytokines were significantly elevated… and methylene blue… significantly lowered both of them.” “This is a proof of concept study, and as a proof of concept, it is strong.” - Key Points Model: OVA + alum sensitization, then inhaled OVA challenge (TH2-driven allergic asthma in mice). Intervention: methylene blue 10 vs 20 mg/kg. Inflammation: reduced BALF leukocytes, especially eosinophils (dose-dependent). Immune signaling: lowered IL-4 and IL-13 (TH2 axis), dose-dependent. Allergy amplifier: lowered OVA-specific IgE (dose-dependent). Oxidative stress: decreased MDA (lipid peroxidation marker). Antioxidant defenses: increased GSH and GPx. Tissue-level confirmation: histology showed less peribronchial/perivascular inflammatory infiltration. Translation caution: murine acute allergic model ≠ clinical asthma outcomes (AHR, symptoms, remodeling). Safety realism: methylene blue has side effects + drug interactions that matter in humans. - Episode timeline 0:34 — Paper setup: asthma + oxidative stress + why methylene blue is interesting <li

What if some of the hardest brain disorders aren’t just “neurotransmitter problems” or “protein problems,” but redox problems — where the NAD⁺/NADH balance drifts, mitochondrial performance declines, oxidative stress rises, and inflammation becomes self-reinforcing? In this Deep Dive, Dr. Mike breaks down a review arguing that bioenergetic failure may be a shared organizing principle across neurodegenerative disease (Alzheimer’s, Parkinson’s, ALS) andpsychiatric illness (schizophrenia, bipolar disorder). We cover why raising NAD in blood isn’t the same as fixing compartmentalized brain redox, why clinical results have been mixed, and why the future of “redox therapy” hinges on biomarker-guided, mechanism-driven trials — not hype. (Educational content only, not medical advice.) - Article Discussed in Episode: Redox therapy for neuropsychiatric disorders: Molecular mechanisms and biomarker development - Key Quotes From Dr. Mike: “The redox system is not peripheral to brain function. It is central to it.” “We still do not fully understand NAD subcellular cycling.” “We lack robust in vivo biomarkers that can really tell us whether a redox-based therapy is engaging its intended target in the brain.” “Raising a precursor in blood is not the same as fixing a dynamic, compartmentalized, disease-specific, energetic failure inside the brain.” “Ketogenic interventions do not just supply alternative fuel. They also appear to influence the NAD plus to NADH ratio.” - Key Points   Redox ≠ generic antioxidants: the paper centers on the NAD⁺/NADH ratio as a core metabolic control variable. Shared energetic bottleneck: different diagnoses may share overlapping mitochondrial dysfunction + oxidative stress + inflammation. Why outcomes are mixed: the field still lacks clarity on subcellular NAD cycling (cytosol vs mitochondria vs nucleus). Biomarkers are the bottleneck: without in vivo target engagement measures in the brain, trials are hard to interpret. Therapy categories discussed: NAD-targeted strategies and ketogenic therapy as redox-modulating interventions. Ketogenic angle: not just alternate fuel — potentially shifts redox state and metabolic flexibility. Precision matters: heterogeneity across patients/stages means treatment should follow mechanism, not label. - Episode timeline 0:34

In this episode of The Energy Code, Dr. Mike connects two papers into one cohesive story: skin aging is largely an energy and mitochondrial quality-control problem, not just a surface-level cosmetic issue. First, a 2025  Experimental Dermatology review explains how UVA and UVB converge on mitochondrial dysfunction — mtROS amplification, mtDNA mutations, membrane potential loss, impaired respiration, inflammatory signaling, senescence, and extracellular matrix breakdown that shows up as wrinkles, thinning, pigment disruption, slower healing, and (at extremes) greater cancer permissiveness. Then a Scientific Reports study puts an intervention on that map: methylene blue in human fibroblasts and 3D skin models appears to reduce mitochondrial ROS, improve proliferation and senescence markers, activate Nrf2-linked antioxidant defenses, and improve tissue-level metrics like viability, dermal thickness, hydration, and elastin-related signals — with clear dose-dependent tradeoffs. The takeaway isn’t hype: it’s a cleaner framework for “skin longevity” built on mitochondrial resilience + redox control + turnover. (Educational content only, not medical advice.) - Articles Discussed in Episode: Role of Mitochondrial Dysfunction in UV-Induced Photoaging and Skin Cancers Anti-Aging Potentials of Methylene Blue for Human Skin Longevity - Key Quotes From Dr. Mike: “Skin aging is not just a surface problem. It is, to a large extent, an energy problem, an oxidative stress problem, and a mitochondrial quality problem.” “UVA penetrates deeper… and tends to cause indirect damage largely through reactive oxygen species.” “UVB is higher energy… and directly damages DNA through lesions like cyclobutane pyrimidine dimers and six-four photoproducts.” “More ROS damages mitochondrial DNA, and damaged mitochondrial DNA tends to worsen mitochondrial function, which then produces more ROS. That is the vicious cycle.” “It (methylene blue) reduced mitochondrial ROS… increased Nrf2-related antioxidant signaling… increased dermal thickness… improved hydration… increased elastin expression.” - Key Points Both papers converge on one thesis: photoaging is a mitochondrial + oxidative stress disorder expressed through skin. UVA vs UVB: UVA = deeper, ROS-heavy “slow burn”; UVB = higher-energy, direct DNA lesions—both end up stressing mitochondria. Vicious cycle: mtROS damages mtDNA → mtDNA damage worsens function → mor

In this Energy Code Deep Dive, Dr. Mike breaks down a mini-review asking a provocative question: could urolithin A support sleep health, indirectly, by improving the biology that makes sleep restorative? The authors don’t claim urolithin A “improves sleep,” and they emphasize a key limitation: there are no direct sleep-outcome studies using EEG, polysomnography, or actigraphy. Instead, they map the pathways that connect urolithin A to sleep-relevant physiology: central circadian clock genes in the SCN, protection against sleep-deprivation–induced neuroinflammation, support for brain mitochondrial integrity and dynamics, and stabilization of the gut microbiota / gut barrier — all systems tightly linked to sleep quality, recovery, and aging. The takeaway isn’t “take urolithin A for sleep.” It’s that the mechanistic groundwork may now be strong enough to justify real sleep trials that measure sleep architecture and circadian markers directly. (Educational content only, not medical advice.) - Article Discussed in Episode: Potential impact of urolithin A on pathways relevant to sleep health: a mini review - Key Quotes From Dr. Mike: “They map out the biological pathways through which urolithin A might influence sleep.” “Urolithin A is not a plant polyphenol in the direct sense. It is a gut microbial metabolite.” “Urolithin A can influence core clock-related genes in the suprachiasmatic nucleus.” “Not because it (urolithin a) is a sedative… but because it may support the deeper biology that makes sleep restorative.” “Sometime in the future — sleep health may not come from forcing the brain to sleep, but from restoring the biology that allows sleep to heal.” - Key Points The paper is hypothesis-building, not a sleep-claims paper. Urolithin A is a gut-derived metabolite from ellagitannins/ellagic acid (pomegranate, berries, nuts). No direct urolithin A sleep studies using EEG / polysomnography / actigraphy were found. Preclinical evidence clusters into 4 domains: SCN clock modulation, sleep-deprivation neuroprotection, mitochondrial integrity, microbiome support. Urolithin A may influence SCN clock genes (e.g., Clock, Cry1, Bmal1) in inflammatory conditions. Sleep deprivation models: urolithin A linked to improved fatigue resistance, lower inflammatory/oxidative markers. Brain resilience: reduced glial activation, lower hip

In this Energy Code Deep Dive, Dr. Mike breaks down a core idea in modern immunology: immune behavior is metabolically gated — and mitochondria sit at the center of that gate. This review reframes mitochondria as active organizers of immune fate, not just “powerhouses,” showing how mitochondrial fusion/fission balance, ROS tone, mtDNA containment vs leakage, trafficking, mitophagy, and even mitochondria-derived extracellular vesicles (mito-EVs) shape whether immune cells become inflammatory, regulatory, resolving, or stuck in chronic dysfunction. You’ll hear how activation often involves a shift toward glycolysis + anabolic metabolism, while resolution leans back into more stable oxidative metabolism, and how “execution hubs” like mTOR/HIF-1α (pro-inflammatory) and AMPK/SIRT1 (restorative/containment) translate metabolic state into inflammatory output. The episode closes with the translational take: the future isn’t blanket immune suppression — it’s context-aware immunomodulation by targeting mitochondrial architecture, quality control, and metabolic checkpoints. (Educational content only, not medical advice.) - Article Discussed in Episode: Metabolic control of immunity and inflammation: Mitochondrial dynamics, pharmacological targets, and therapeutic opportunities - Key Quotes From Dr. Mike: “The immune system is not just responding to receptors… it is responding through metabolism.” “Metabolism does not just correlate with inflammation, metabolism gates inflammation.” “Mitochondrial integrity becomes the point where upstream immune and metabolic signals are converted into irreversible inflammatory cell death.” “Resolution of inflammation is not only about removing the initial trigger, it is also about reconstituting the mitochondrial architecture that supports homeostasis.” “Immune regulation is not only a matter of what the immune system sees, it is also a matter of what the mitochondria allow.” - Key Points Immune activation isn’t just signaling → it’s metabolic state–dependent, centered on mitochondria. Mitochondria act as decision platforms: ATP, ROS, intermediates, membrane potential, mtDNA integrity. Metabolic inflammatory checkpoints: metabolism doesn’t just correlate with inflammation — it gates it. Activation often shifts toward glycolysis; resolution often favors OXPHOS and resilient mitochondrial networks. mTOR/HIF-1α reinforce glycolysis and inflammatory programming (e.g., IL-

In this Deep Dive, Dr. Mike breaks down a frontier idea in mitochondrial medicine: ocular mitochondrial transplantation — isolating healthy mitochondria and delivering them into specific eye compartments to support bioenergetics in tissues like the retina, retinal pigment epithelium (RPE), and optic nerve head. The promise is obvious: mitochondrial dysfunction shows up across major blinding diseases (AMD, glaucoma/optic neuropathies, diabetic retinopathy), and these tissues are some of the most energy-demanding in the body. But the real focus of this paper is not hype, it’s delivery. The episode walks through what the evidence suggests so far about route-dependent targeting: intravitreal delivery trending toward inner retina/optic nerve head exposure, subretinal delivery aligning with outer retina/RPE exposure, and suprachoroidal delivery looking technically feasible but still biologically unproven for true retinal/RPE uptake. You’ll also hear the key unanswered questions that determine whether this becomes clinical reality: uptake vs signaling effects, persistence/durability, dosing, and immune safety in a tissue with minimal tolerance for inflammation. (Educational content only, not medical advice.) - Article Discussed in Episode: Mitochondrial Transplantation in the Eye: A Review and Evaluation of Surgical Approaches - Key Quotes From Dr. Mike: “Therapeutic mitochondrial transplantation is, in a sense, taking an existing biological logic and trying to harness it intentionally.” “That means the mitochondria are not some side note in ophthalmology, they are central players.” “You cannot just say put mitochondria into the eye and assume they will reach the right place.” “Intravitrial delivery is probably the most relevant route if your therapeutic target is retinal ganglion cells… or the proximal optic nerve.” “Suprachoroidal delivery appears technically promising, but still biologically uncertain with respect to actual retinal or RPE uptake.” “The concept is biologically plausible, surgically approachable, and anatomically root-dependent.” - Key Points The eye is an extreme bioenergetic environment; mitochondrial failure can map directly onto vision failure. Mitochondrial dysfunction is implicated across AMD, glaucoma/optic neuropathies, diabetic retinopathy, and age-related retinal decline. Horizontal mitochondrial transfer is a real biological phenomenon (TNTs, EVs, free mitochondria), not just theory. <p class="p1

Aging isn’t just “mitochondria wearing out.” This Deep Dive reframes the real problem as mitochondrial quality control (MQC): the coordinated network that builds, reshapes, repairs, and clears mitochondria so tissues stay resilient over time. We walk through how aging disrupts that architecture: biogenesis becomes less coordinated, mitochondrial networks fragment, mitophagy and lysosomal clearance slow, proteostasis erodes, and the result is a more inflammatory, less adaptive cellular environment. Then we get practical: the paper argues exercise is powerful because it remodels MQC, not merely because it increases mitochondrial content. You’ll hear how endurance training, HIIT, and resistance training each bias MQC differently — endurance for sustained oxidative remodeling, HIIT for sharp signaling/clearance cycles, and strength training for structural and proteostatic support — suggesting the most durable anti-aging strategy is often multimodal, not one-dimensional. (Educational content only, not medical advice.) - Article Discussed in Episode: The role of exercise-mediated mitochondrial quality control remodeling in aging - Key Quotes From Dr. Mike: “Aging is not just a story of damage… it is also a story of reduced repair, reduced renewal, reduced clean-up.” “Mitochondrial biogenesis is not just about making more mitochondria. It is about making good mitochondria.” “Exercise may improve both the front end and the back end of mitochondrial quality control.” “Declining mitochondrial quality control is not only a bioenergetic problem, it is also an inflammatory problem.” “Exercise is reteaching the system how to manage mitochondria… how to restore coordination across the quality control network.” - Key Points MQC is a multi-tier network: biogenesis + fusion/fission + mitophagy + proteostasis + organelle communication. Aging creates disorganization, not just “less ATP.” Fragmentation rises (↓ fusion proteins like OPA1/MFN; ↑ DRP1 signaling), weakening resilience. Mitophagy can “tag” damage, but later steps fail with age (flux/lysosomes), increasing inflammatory spillover. Exercise reactivates upstream signals (AMPK/P38/SIRT1 → PGC-1α/TFAM programs). Exercise-ROS is framed as adaptive signaling, not purely damage. Endurance vs HIIT vs resistance: different MQC emphases → likely best results with c

Most people think mitochondrial quality control is one story: mitophagy — tag the bad mitochondria, swallow them, degrade them in lysosomes. This Deep Dive expands the map. In the heart, where mitochondria take up ~⅓ of cardiomyocyte volume and ATP demand is relentless, cells use two routes to prevent a buildup of dysfunctional, ROS-leaking mitochondria: (1) intracellular degradation through multiple mitophagy and lysosome-linked pathways, and (2) extracellular secretion, where damaged mitochondria are exported — often inside extracellular vesicles — especially when internal clearance is overwhelmed. We walk through the classic PINK1–Parkin stress-response pathway, the “baseline housekeeping” systems that keep the heart clean even without overt stress, the concept of “releasing the brakes” on mitophagy (like USP30), and alternative routes such as RAB9-dependent alternative autophagy and endosomal/ESCRT-linked mitochondrial clearance. Then we hit the most provocative shift: secretion as a true quality-control strategy — with evidence from cardiac stress, myocardial infarction, and lysosome-impaired states like LAMP2 deficiency. The big takeaway: mitochondrial health isn’t only about producing energy, it’s about knowing when (and how) to remove what can’t be trusted. (Educational content only, not medical advice.) - Article Discussed in Episode: Two Routes for Removing Unhealthy Mitochondria: Degradation and Secretion - Key Quotes From Dr. Mike: “What does a cell do with mitochondria that are no longer healthy enough to keep?” “Cells, and especially heart cells, rely on two major routes to remove unhealthy mitochondria.” “The field is shifting from a one-route model to a two-route model.” “Mitophagy is the selective degradation of dysfunctional mitochondria.” “A heart cannot wait for a crisis to clean up its mitochondria.” - Key Points The heart runs on mitochondrial integrity: damaged mitochondria → ↓ATP efficiency, ↑ROS, impaired contraction, inflammation, and cell loss risk. Two routes for removal: degradation (mitophagy/lysosomes) and secretion (export via extracellular vesicles). PINK1–Parkin = stress mitophagy: membrane potential collapse → PINK1 accumulation → Parkin ubiquitination → adaptor recruitment → autophagosome → lysosome. Baseline mitophagy exists beyond PINK1/Parkin (the heart can’t wait for “crisis cleanup”). USP30 acts like a brake on ubiquitin signaling; inhibiting it can restore mitophagy in pathology mod

In this illuminating episode of The Energy Code, Dr. Mike  spotlights a next-gen longevity ingredient that almost nobody is talking about correctly: gold nanoparticles. Not colloidal gold. Not “gold masks.” True ~10nm gold nanospheres — small enough to behave like a plasmonicmaterial that can interact with light and electromagnetic energy in ways bulk gold simply can’t. Mike breaks down why nano-gold isn’t just a trendy add-on, but a potential bioenergetic platform: a light-responsive ingredient that may help shape the skin’s microenvironment by influencing oxidative stress, inflammatory signaling, wound-repair pathways, and collagen/elastin biology. He also explains why this matters for real-world anti-aging: skin aging is driven by mitochondrial decline + excess free radicals, leading to inflammation, collagen breakdown, and cellular senescence. Nano-gold is positioned as a “conductor” in that system—an ingredient that may help organize energy and improve how the skin handles light exposure, especially when paired with a high-performance base formula. The episode also introduces BioLight Gold Mist —a new skin serum built around nano-gold and designed to be used with the BioLight Mystic Nano Misting Device to maximize absorption. You’ll hear how the formula stacks advanced hydration + antioxidant defense + cellular resilience, with gold nanoparticles as the centerpiece that ties the entire system together. (Educational content only, not medical advice.) - Book Discussed in Episode: Gold: Catalyst of Radiant Health by Victor Sagalovsky - Key Quotes From Dr. Mike: "Aging skin is largely driven by… oxidative stress, chronic inflammation, collagen breakdown, and cellular senescence. "Gold nanoparticles… in terms of skincare is like going from the wagon wheels of the Oregon Trail to a self-driving car." "Gold nanoparticles interact with light through something called localized surface plasmon resonance." "So instead of light just passing over your skin… you now have (gold) particles that can capture light, concentrate it, and convert it into usable energy at the local level." Regarding Gold Mist: "We’re creating a light-responsive, energy-aware interface between the environment and your biology." - Key Points This is not colloidal gold: the episode emphasizes 10nm gold nanoparticles as a different category with different behavior. Product reveal: BioLight’s Gold Mist launches as a “sister/cousin” to Blue Mist, swapping methylene blue for nano-gold while keeping the same base stack. Sys

This Deep Dive reframes COVID-19 pneumonia as more than infection + inflammation. The review argues SARS-CoV-2 targets mitochondria early, reprogramming mitochondrial gene expression, interacting with mitochondrial proteins, suppressing oxidative phosphorylation (especially Complex I), driving excess fission/fragmentation, and activating mitochondria-linked apoptosis. The most clinically striking link is physiology: mitochondrial Complex I oxygen sensing in pulmonary artery smooth muscle helps drive hypoxic pulmonary vasoconstriction (HPV) — a mechanism that optimizes ventilation/perfusion matching. If that mitochondrial sensing breaks, HPV weakens, shunting increases, and hypoxemia can become profound — sometimes with “silent hypoxia.” The paper also connects mitochondrial disruption to long COVID as a persistent energetic injury pattern and highlights therapeutic angles aimed at restoring HPV and reducing mitochondrial death signaling. (Educational content only, not medical advice.) - Article Discussed in Episode: SARS-CoV-2 targets mitochondria, exacerbating COVID-19 pneumonia - Key Quotes From Dr. Mike: “SARS-CoV-2 is not just infecting airway cells and triggering inflammation. It is also targeting… the mitochondria.” “That mitochondrial targeting is not a side effect. It is central to the disease process.” “The virus is actively reshaping the mitochondrial network into a more fragile, more fragmented, more failure-prone state.” “The pneumonia is no longer just inflammatory. It is bioenergetic and apoptotic.” “If we want to fully understand severe viral pneumonia, we need to look… at the mitochondrial machinery caught in between.” - Key Points Core thesis: SARS-CoV-2 targets mitochondria, and that’s central — not incidental — to severe pneumonia. Early event: within hours, infection dysregulates nuclear-encoded mitochondrial genes (ETC/ATP/membrane pathways). Direct sabotage: viral proteins localize to mitochondria and impair Complex I, dynamics, and permeability pathways. Energetic collapse: reduced OXPHOS → lower ATP/respiration → airway cells become unstable under stress. Dynamics shift: infection pushes excess DRP1-driven fission → fragmentation → ROS rise + apoptosis readiness. Apoptosis is multimodal: AIF (caspase-independent) + caspase activation (caspase-dependent). Repair gets blocked: viral effects on the cell cycle may impair regeneration after injury.

Liver cancer (especially HCC) isn’t just uncontrolled growth, it’s mitochondrial adaptation. This Deep Dive breaks down how tumors repurpose mitochondrial defects (impaired OXPHOS, ROS imbalance, mtDNA damage, altered membrane potential, dysregulated mitophagy, calcium chaos) into a survival architecture that fuels proliferation, invasion, immune signaling, and drug resistance. We also map the therapeutic frontier: when to reduce oxidative injury (pre-malignant terrain) versus when to push tumor cells over the edge (pro-oxidant, ETC targeting, apoptosis re-sensitization), and why the future is precision + combinations, not one magic bullet. (Educational content only, not medical advice.) - Article Discussed in Episode: Targeting mitochondrial dysfunction to intervene in liver cancer - Key Quotes From Dr. Mike: “Liver cancer is not just a disease of uncontrolled cell growth; it is also a disease of mitochondrial failure, mitochondrial adaptation, and mitochondrial hijacking.” “Mitochondria are central operating systems in the liver.” “Mitochondrial dysfunction may be part of the terrain that makes liver carcinogenesis more likely in the first place.” “Mitochondrial dysfunction does not simply weaken the cell, it pushes the cell into a different metabolic program that may actually favor malignancy.” “Liver cancer does not merely tolerate mitochondrial dysfunction — it uses it.” - Key Points Liver cancer is a mitochondrial disease in disguise: dysfunction becomes adaptation, then hijacking. OXPHOS defects (often Complex I/III) → electron leakage → ROS rise, which both damages and signals. ROS is dual-use: it can drive survival pathways at moderate levels and become lethal at high levels. Warburg shift is strategic: glycolysis supports rapid ATP + anabolic building blocks + flexibility. Abnormal membrane potential helps block apoptosis by stabilizing mitochondria and resisting cytochrome-c release. mtDNA damage is a self-amplifying loop: mtDNA injury worsens ETC stability → more ROS → more damage. Mitophagy is stage-dependent: tumor-suppressive early, potentially tumor-supportive once cancer is established. Calcium dysregulation (ER→mitochondria transfer, overload) drives stress signaling without necessarily triggering death due to anti-apoptotic buffering. Therapeutic directions: ETC targeting, redox strategies (anti- vs pro-oxidant), mtDNA

In this Energy Code Deep Dive, Dr. Mike breaks down a major shift in cancer biology: mitochondria aren’t static “powerhouses”, they’re a dynamic network that tumors actively remodel to drive survival. Based on the review “Mitochondrial Dynamics and Cancer Mechanisms and Targeted Therapy,” we explore how cancer systematically tilts mitochondrial behavior toward hyperactive fission (DRP1), reduced fusion (MFN1/2, OPA1 disruption), altered mitophagy, and directed transport — and how that network remodeling supports the core hallmarks of malignancy: metabolic plasticity, rapid proliferation, apoptosis resistance, invasion/metastasis, therapy resistance, and immune evasion. We then walk through the therapeutic frontier: fission inhibitors (e.g., DRP1-targeting approaches), fusion-promoting strategies, mitophagy modulation, and why combination therapy and tumor-specific mitochondrial phenotyping are the future — because the same mitochondrial shift can help in one tumor type and backfire in another. (Educational content only, not medical advice.) - Article Discussed in Episode: Mitochondrial dynamics and cancer: mechanisms and targeted therapy - Key Quotes From Dr. Mike: “Cancer is not chaos. It’s strategic adaptation.” “Cancer… is also a disease of mitochondrial network remodeling.” “The dominant pattern… is hyperactive fission, reduced fusion, altered mitophagy, and enhanced directed transport.” “Mitochondrial fission supports tumor cell division.” “Moderate mitochondrial ROS becomes a signal that activates protective adaptation.” - Key Points Cancer is organized by mitochondrial behavior — shape, movement, recycling, and compensation — not just mutations. Tumors often show hyperactive fission (DRP1↑) + fusion impairment (MFN1/2↓, OPA1 dysregulated) → fragmented networks that support malignancy. Morphology ≠ function: tumors can keep oxidative metabolism high despite fragmentation by upregulating respiratory assembly factors (a “morphology–function decoupling”). Mitochondrial dynamics enable metabolic plasticity, helping tumors adapt to hypoxia, nutrient stress, chemo, and immune pressure. Proliferation: fission supports rapid division by distributing mitochondria to daughter cells. Metastasis: fragmented mitochondria localize to the leading edge to power migration and cytoskeletal remodeling. <p clas

In this Energy Code Deep Dive, Dr. Mike explores a frontier idea in regenerative medicine: mitochondrial transplantation — the transfer of viable mitochondria into injured tissue to restore bioenergetic function. Using the review “Mitochondrial Transplantation in Lung Diseases: From Mechanisms to Application Prospects,” we map why the lungs are uniquely vulnerable to oxidative injury, how mitochondrial dysfunction becomes an engine for inflammation (via mtDNA danger signals), and why restoring mitochondria could interrupt the self-reinforcing triangle of oxidative stress → mitochondrial failure → inflammatory signaling. We also break down how mitochondrial transfer already occurs naturally (tunneling nanotubes, extracellular vesicles), what donor sources and isolation methods mean for real-world feasibility, and why lung delivery may be uniquely promising — especially the possibility of airway/aerosol routes. Finally, we walk disease-by-disease through the evidence landscape (COPD, asthma, ARDS, ischemia-reperfusion injury, pulmonary hypertension, fibrosis) and the major constraints that still define this field: viability windows, storage challenges, dosing/standardization, and immune compatibility. (BioLight framework tie-in: mitochondria-first thinking without hype—mechanism, delivery, and outcomes.) (Educational content only, not medical advice.) - Article Discussed in Episode: Mitochondrial transplantation in lung diseases: From mechanisms to application prospects - Key Quotes From Dr. Mike: “The lungs live under constant oxidative pressure... Mitochondria are not just passive victims of oxidative stress, they are also active generators of it.” “Lung disease… is a self-reinforcing triangle of oxidative stress, mitochondrial dysfunction, and inflammatory signaling.” “Mitochondrial transplantation [is] the transfer of viable, intact, functioning mitochondria into damaged cells.” “Aerosol-based mitochondrial delivery… opens the door to a non-invasive route to bioenergetic rescue.” “If we want to truly change the trajectory of chronic lung disease, we may need to… start repairing the energy system itself.” - Key Points Lung disease is often a bioenergetic disease: oxidative stress, mitochondrial dysfunction, and inflammation reinforce each other. Mitochondria are both victims and sources of ROS, creating a vicious loop of self-damage and escalating oxidative burden. mtDNA escape is inflammatory fuel,

This Deep Dive breaks down a 2015 – late 2025 systematic review asking a modern longevity question: could metformin — best known as a first-line type 2 diabetes drug — help preserve vision by protecting mitochondrial function in age-related macular degeneration (AMD)? The episode frames AMD as a cellular stress + mitochondrial dysfunction + oxidative overload problem centered on the metabolically intense retinal pigment epithelium (RPE). You’ll hear the review’s three main takeaways: (1) metformin often reduces ROS and inflammatory signaling in RPE models, (2) it may preserve mitochondrial structure/function via AMPK, biogenesis, autophagy/mitophagy, and (3) observational human studies associate metformin use with lower AMD risk (especially dry AMD)—with crucial caveats. The key nuance: metformin is context-dependent; in certain severe injury models, its complex I inhibition can worsen mitochondrial damage. The result is not “metformin is the answer,” but “metformin may reveal the levers that matter most for retinal aging.” (Educational content only, not medical advice.) - Article Discussed in Episode:   Effects of Metformin on Mitochondrial Health and Oxidative Stress in Age-Related Macular Degeneration: A Systematic Review - Key Quotes From Dr. Mike: “AMD is not just an eye disease… it is a disease of mitochondrial dysfunction… oxidative overload… chronic inflammation.” “Metformin appears to reduce oxidative stress and inflammatory signaling in retinal pigment epithelial cells.” “Metformin has also become one of the most discussed drugs in longevity science… AMPK, mitochondrial metabolism, autophagy, oxidative stress, inflammation.” “Many of the cell studies used metformin concentrations far above what is typically reached in human plasma.” “Metformin may be pointing us toward a therapeutic principle.” “If we want to preserve vision as we age, we may have to think… about [the retina] as a mitochondrial system under chronic stress.” - Key Points AMD as systems aging: not just “eye disease,” but oxidative stress + mitochondrial decline + chronic inflammation—especially in the RPE. Why metformin is interesting: longevity-relevant pathways (AMPK, autophagy/mitophagy, oxidative stress, inflammation). Review scope: systematic review of studies 2015–late 2025, including observational human data + RPE/AMD-relevant experimental models. C

What if osteoarthritis isn’t primarily a “wear and tear” problem, but a mitochondrial problem inside living joint tissue? In this episode, Dr. Mike Belkowski connects five distinct (but converging) strategies through one lens: joint degeneration as an energy + redox + immune-metabolic disorder. You’ll hear how oxidative stress can act like an upstream “wiring harness” for inflammation, why intra-articular methylene blue may modulate pain signaling and cytokines, how urolithin A links mitophagy to cartilage protection, why mitochondrial transplantation is the boldest (and earliest) frontier, and how intra-articular photobiomodulation aims to deliver photons where penetration limits usually break the signal. The takeaway: if mitochondria shape brain, muscle, and longevity, they also shape mobility — and the future of OA care may shift from symptom management to energetic restoration. (Educational content only, not medical advice.) - Articles Discussed in Episode: From concept to practice: intra-articular photobiomodulation for knee osteoarthritis Mitochondrial transplantation for osteoarthritis: from molecular mechanisms to clinical translation Urolithin A improves mitochondrial health, reduces cartilage degeneration, and alleviates pain in osteoarthritis Methylene blue relieves the development of osteoarthritis by upregulating lncRNA MEG3 Water-soluble fullerene (C60) inhibits the development of arthritis in the rat model of arthritis - Key Quotes From Dr. Mike: “What happens when we stop thinking about osteoarthritis as just a wear and tear problem and start thinking about it as a, a mitochondrial problem?” “Oxidative stress is not just collateral damage in joint disease. It is part of the engine driving the disease.” “If mitochondrial dysfunction is part of osteoarthritis, then one logical question is whether cleaning up defective mitochondria can restore healthier joint cell function.” “Osteoarthritis and inflammatory joint degeneration are not only structural disorders, they are energy disorders, redox disorders, signaling disorders, and immune metabolic disorders.” “The future is probably not one silver bullet. It is a coherent mitochondrial framework.”<

This Deep Dive introduces resveratrone, a newly described compound created via photoconversion of resveratrol. The paper’s core argument is that resveratrone is structurally distinct enough to behave like a different molecule — and in a suite of skin-relevant assays (antioxidant capacity, melanin/tyrosinase biology, fibroblast activity, collagen synthesis, and acne-associated antimicrobial effects), it often outperforms resveratrol. Importantly, this is not a long-term human outcomes study; it’s an early mechanistic/performance comparison. Still, the profile is compelling: unusually strong DPPH radical scavenging (even compared to vitamin C under the reported conditions), measurable pigment-pathway effects, a notable signal around fibroblasts + type I collagen, and stronger inhibition of acne-associated bacteria. The episode closes with the right stance: promising signal → needs independent replication, formulation/penetration data, and clinical validation. (Educational content only, not medical advice.) - Article Discussed in Episode: Unveiling Resveratrone: A High-Performance Antioxidant Substance - Key Quotes From Dr. Mike: “It is centered on a compound called resveratrone, which was discovered through the photoconversion of resveratrol.” “When structure changes, biologic behavior can change dramatically—and that’s the entire premise here.” “In most of these areas, resveratrone outperformed resveratrol.” “Resveratrone showed extremely strong radical scavenging activity, even at low concentrations... It also outperformed ascorbic acid, vitamin C, under the same testing conditions.” “It does not establish optimal topical formulation, stability over time, skin penetration in vivo, or ideal dosing.” - Key Points Resveratrone is discovered via photoconversion of resveratrol and may behave as a different molecule, not a minor variant. This is early-stage evidence: biochemical/cellular assays, not long-term human clinical outcomes. Antioxidant capacity: strong DPPH radical scavenging; reported to beat resveratrol and even vitamin C in the assay conditions. Pigment biology: reduces melanin in α-MSH–stimulated B16F10 cells; includes tyrosinase inhibition signal. Nuance: the paper notes not every endpoint is uniformly superior in all comparisons (some whitening comparisons are mixed). Regeneration signals: resveratrone increased fibroblast proliferation/activity and type I collagen synthesiswhere resveratrol did not in the same conditions (p

This Deep Dive breaks photoaging out of the “cosmetic” category and reframes it as a systems-level loss of cellular resilience driven by ultraviolet exposure and mitochondrial stress. UVA and UVB create different injury patterns — UVB skewing toward more direct DNA damage in the epidermis, UVA driving deeper dermal oxidative stress that impacts fibroblasts and collagen architecture. The paper’s central thesis is bidirectional: UV damages mitochondria, and damaged mitochondria amplify UV injury through ROS, which creates a self-reinforcing loop that accelerates senescence, apoptosis, and matrix breakdown. The practical future of anti-photoaging therapy, according to this review, is mitochondria-forward: protect mtDNA, reduce ROS at the source, preserve membrane potential, and support mitochondrial quality control (especially mitophagy). (Educational content only, not medical advice.) - Article Discussed in Episode: Interplay of Skin Aging: Mitochondrial Stress and Ultraviolet Exposure - Key Quotes From Dr. Mike: “Sun exposure does not just age the skin from the outside in, it ages the skin from the inside out.” “Photoaging… is a bioenergetic event.” “It is a vicious cycle between ultraviolet exposure and mitochondrial dysfunction with reactive oxygen species… as one of the key amplifiers of damage.” “The authors described this as bidirectional… UV exposure damages mitochondria, but damaged mitochondria also amplify UV induced injury.” “Wrinkles are not just wrinkles, they may be the visible endpoint of cumulative mitochondrial injury.” “If that is true, then the future… may depend less on masking damage and more on restoring mitochondrial resilience.” - Key Points Photoaging is inside-out: UV triggers mitochondrial stress that amplifies aging biology. UVA vs UVB: UVA penetrates deeper → dermal oxidative stress; UVB → higher-energy, more direct DNA injury. Mitochondria are stress integrators, not just ATP producers (redox, apoptosis, calcium, dynamics, mitophagy). Core loop: UV → ROS → mtDNA/protein/membrane damage → impaired mitochondria → more ROS → accelerated decline. mtDNA injury is central (including the “common deletion” 4,977 bp, plus mutations/D-loop lesions/heteroplasmy). Downstream consequences include apoptosis (BCL-2 family shift → cytochrome c → caspases) and tissue-level fibroblast loss. Mitophagy (PINK1/Parkin) is protective; dysregulation leave

This Deep Dive reframes age-related macular degeneration (AMD) as more than “aging eyes” or vascular/inflammatory drift. The core argument: AMD may be a mitochondrial quality-control disease, especially in the retinal pigment epithelium (RPE), which is the high-demand support layer that keeps photoreceptors alive. As mitochondrial dynamics break down (excess fission, reduced fusion, reduced biogenesis, failing mitophagy), damaged mitochondria accumulate, ROS rises, mitochondrial danger signals spill into immune pathways, and complement activation becomes chronic — creating a self-reinforcing loop that ends in RPE failure and photoreceptor loss. The most important implication is timing: by the time structural damage is visible, the energetic failure has likely been unfolding for years, meaning the real therapeutic window may be earlier, at the level of mitochondrial resilience. (Educational content only, not medical advice.) - Article Discussed in Episode: Mitochondrial dynamics and their role in the pathogenesis of age-related macular degeneration: A comprehensive review - Key Quotes From Dr. Mike: “(This article) frames AMD as a disease of mitochondrial breakdown... More specifically, it frames AMD as a disease of failed mitochondrial quality control.” “This is where the paper becomes especially powerful… it treats it as a central engine of the disease process.” “The retina has very little room for error.” “By the time you are looking at advanced dry AMD… the visible anatomy is already reflecting a much older, energetic failure.” “If we want to preserve vision, we may need to preserve mitochondrial intelligence first.” - Key Points AMD is framed as mitochondrial breakdown, not just “wear and tear” or late-stage anatomy. The RPE is the key vulnerability hub: heavy workload + high oxidative environment = little margin for error. “Mitochondrial dynamics” = fission, fusion, biogenesis, mitophagy (quality control). AMD models show hyper-fission (DRP1-driven) → fragmented mitochondria → ↓ATP, ↑ROS. Reduced fusion proteins (mitofusins/OPA1) → less network repair, less crista stability. Downregulated biogenesis (PGC-1α signaling) → fewer healthy replacements when demand is highest. Mitophagy failure (PINK1/Parkin bottleneck + lysosomal decline) → damaged mitochondria accumulate. Accumulated damage releases mitochondrial DAMPs → cGAS–STING / T

Oral infections aren’t “just a mouth problem” — they’re biofilm problems, delivery problems, and resistance problems. This Deep Dive breaks down a review on photosensitized methylene blue nanoparticles as a next-generation approach for controlling oral pathogens. Instead of relying on free methylene blue (which can disperse fast, stain, and fall short in biofilms), the paper explores methylcellulose nanoparticles engineered for near-complete encapsulation, tunable particle size, and sustained release, then activated with 660 nm light to generate microbe-killing reactive oxygen species. The key takeaway: the future of photodynamic therapy in dentistry won’t be driven by light alone — it’ll be driven by smarter delivery systems that improve retention, penetration, and precision. (Educational content only, not medical advice.) - Article Discussed in Episode: Photosensitized Methylene Blue Nanoparticles: A Promising Approach for the Control of Oral Infections - Key Quotes From Dr. Mike: “Oral infections are not small issues… the mouth is one of the most microbially active environments in the body.” “Biofilms are one of the hardest clinical realities in oral medicine.” “Once biofilms mature, conventional antimicrobial approaches often start to lose efficiency.” “This paper is focused… using methylene blue not as a free dye in solution but encapsulated inside methyl cellulose nanoparticles.” “You are no longer just asking whether methylene blue works. You are asking how to shape its behavior in time.” “The nanoparticles performed better than pure methylene blue.” - Key Points Oral infections are biofilm-driven and often become harder to treat as biofilms mature. The paper asks: can nanoparticle delivery make methylene blue more stable, better retained, and more effective? Near-100% encapsulation efficiency suggests the payload is actually protected inside the carrier. Loaded particles measured roughly 186–274 nm; smaller/more uniform particles are positioned for stronger interaction and faster release. Sustained release >10 hours and tunable behavior: smaller particles released far more MB over the same window than larger ones. In antimicrobial testing, MB nanoparticles outperformed free methylene blue (especially with light activation), sometimes dropping counts below detection. Mechanism: 660 nm activation → ROS (singlet oxygen/f

Most people think circadian rhythm is just “sleep timing.” This Deep Dive flips that model on its head using a plant biology review with a human-relevant message: energy is not just about fuel — energy is about timing. The circadian clock doesn’t simply respond to sunlight; it’s shaped from the inside by metabolic cues from chloroplasts and mitochondria — sugars, redox state, ROS, organic acids, and cellular energy status. The result is a living loop: light tunes metabolism, metabolism tunes the clock, and the clock re-schedules metabolism. The real takeaway: resilience isn’t rigid perfection, it’s coordinated complexity. (Educational content only, not medical advice.) - Article Discussed in Episode: Metabolism in Sync: The Circadian Clock, a Central Hub for Light-Driven Chloroplastic and Mitochondrial Entrainment - Key Quotes From Dr. Mike: “Energy is not just about having fuel. Energy is also about timing.” “The circadian system is not simply being pushed around by light from the outside.” “The chloroplast is not just a photosynthetic organelle, it is also a timing organelle.” “Mitochondria are not only engines, they are sensors.” “The goal is not to eliminate ROS entirely. The goal is rhythmic redox balance.” “Living systems do not thrive simply because they have energy. They thrive because they know how to coordinate energy in time.” - Key Points Energy is timing, not just fuel: healthy biology anticipates; it doesn’t only react. Circadian rhythm is a loop: the clock regulates metabolism and metabolism feeds back into the clock. Metabolism is information: sugars, redox shifts, ROS, ATP availability, and organic acids act as timing cues. Sugar can “set” the clock: even in darkness, sucrose can sustain rhythmic clock gene expression—and timing of sucrose shifts the phase. Chloroplasts + mitochondria aren’t just workers: they’re active participants in circadian entrainment and timing signals. Rhythmic redox balance matters: the goal isn’t “no ROS,” it’s controlled, rhythmic ROS + rhythmic antioxidant defense. Coordination beats optimization: efficiency comes from synchronizing interdependent processes (e.g., photorespiration across organelles). Big implication: what matters is not only what input you provide, but when the organism is most prepared to use it (chronoculture). - Episode timeline <u

Hashimoto’s thyroiditis is usually treated like a numbers problem: TSH normalizes, levothyroxine is “working,” end of story. But many patients live in a different reality: persistent fatigue, poor sleep, brain fog, low mood, pain, and a feeling of being drained even when labs look fine. In this Deep Dive, Dr. Mike breaks down a study that tested photobiomodulation (PBM) applied over the thyroid region as an adjunct to standard treatment. The key focus wasn’t just lab values — it was how people actually felt: fatigue severity, fatigue impact, sleep quality, daytime sleepiness, anxiety, depression, and pain. Both sham and active groups improved (placebo and therapeutic attention are real), but the active PBM group improved more across every major symptom category, suggesting a broader shift in underlying physiology — likely involving mitochondrial function, oxidative stress, and inflammatory signaling. Bottom line: this isn’t “light replaces medicine.” It’s a serious look at what happens when replacement therapy corrects a piece of the picture, but the energetic terrain still needs support. (Educational content only, not medical advice.) - Article Discussed in Episode: The effect of photobiomodulation therapy on fatigue and behavioural status in patients with Hashimoto’s thyroiditis - Key Quotes From Dr. Mike: "This paper doesn’t frame Hashimoto’s only as a hormone problem — it points to inflammation, oxidative stress, and mitochondrial dysfunction.” “The active photobiomodulation group improved more; across every major symptom category measured.” “When you see energy, mood, sleep, and pain shift together, you’re not looking at a narrow effect — you’re looking at a deeper physiological influence.” “Hormone replacement may correct part of the picture, but not always restore cellular energy dynamics.” “Healing isn’t just bringing a number into range. Healing is restoring function.” - Key Points Hashimoto’s isn’t only a hormone story — persistent symptoms may reflect inflammation, oxidative stress, and mitochondrial strain even when labs normalize. Study design: PBM + levothyroxine vs sham + levothyroxine, applied over the thyroid region 2x/week for 3 weeks. Outcomes prioritized real life symptoms: fatigue (severity + impact), sleep quality, daytime sleepiness, anxiety, depression, pain. Both groups improved, reinforcing the role of expectation/attention/placebo. Ac

Most weight-loss advice stops at “calories in vs. calories out.” In this episode, Dr. Mike goes deeper: what happens to your body’s energy machinery during weight loss and why maintenance can be harder than the initial drop. Using four papers (two skeletal muscle mitochondrial studies, one PBM body-contouring study, and one chlorin e6 photodynamic obesity study in mice), you’ll learn how weight loss can lower energy expenditure, remodel mitochondrial membranes (cardiolipin), shift efficiency and coupling, and produce totally different adaptations depending on whether the weight came off via lifestyle or bariatric surgery. The headline: weight loss is an adaptive bioenergetic event, not just a subtraction problem — and mitochondria sit in the middle of the outcome. (Educational content only, not medical advice.) - Articles Discussed in Episode: Human Skeletal Muscle Mitochondria Responses to Weight Loss Induced by Bariatric Surgery or Lifestyle Intervention Weight loss increases skeletal muscle mitochondrial energy efficiency in obese mice Photobiomodulation Therapy for Improvement of Body Contour: A Retrospective Study on Middle Eastern Participants Anti-Obesity Effect of Chlorin e6-Mediated Photodynamic Therapy on Mice with High-Fat-Diet-Induced Obesity - Key Quotes From Dr. Mike: “Body composition is downstream of energy biology.” “Weight loss is not just a subtraction problem, it’s an adaptive biological event.” “After weight loss, the body isn’t just smaller — it’s more economical.” “Maintenance is part of the weight-loss intervention, not the chapter after.” “Don’t just ask whether something helps you lose weight—ask what it teaches your body to do with energy.” - Key Points Weight loss ≠ simple subtraction: it triggers adaptive biology (hormones, fuel use, expenditure, defense mechanisms). Mitochondria are central: not just ATP—also redox regulation, signaling, substrate use, heat generation, stress response. Post-weight-loss “efficiency” can backfire: more efficient mitochondria can mean lower energy expenditure, making maintenance harder. Membrane biology matters: cardiolipin remodeling (e.g., tetralinoleoyl cardioli

Transcranial photobiomodulation (tPBM) is everywhere in performance culture —shine near-infrared light on the prefrontal cortex and supposedly you get better oxygenation, lower perceived effort, delayed central fatigue, and improved endurance. This Deep Dive episode breaks down a clean, double-blind crossover study in trained cyclists who rode their own bikes through a standardized constant-load effort followed by a 25-minute time trial. The conclusion was clear: acute tPBM at 810nm (40Hz, 20 minutes, with an intranasal component) did not improve performance, heart rate, lactate, perceived exertion, or pacing dynamics versus sham. The real value is what the null result teaches: dose, penetration, target engagement, and context matter —especially in trained athletes. (Educational content only, not medical advice.) - Article Discussed in Episode: Effects of transcranial photobiomodulation on performance and cardiovascular responses in trained cyclists - Key Quotes From Dr. Mike: “Does it (tPBM) actually work in real athletes under real performance conditions with real outcomes like power, heart rate, and pacing?” “Can enough light penetrate scalp and skull to meaningfully modulate cortical function?” “Parameters matter, penetration matters, and athletes are a hard population to move.” “Wavelength and irradiance aren’t specs for marketing — they’re the difference between signal and nothing.” - Key Points Clean test of hype: trained cyclists, double-blind, randomized crossover, real performance outcomes. Protocol: 20 min tPBM (810nm, 40Hz; prefrontal targeting + intranasal probe), then warm-up → 15-min constant load → 25-min time trial. Result: no meaningful differences vs sham in power, HR, lactate, RPE, or efficiency-style ratios. Likely explanations: insufficient cortical photon dose/penetration, parameter selection (wavelength/irradiance), acute vs chronic effects, no direct confirmation of brain “target engagement,” athlete ceiling effects. Takeaway: null results are useful—optimize parameters, verify engagement (fNIRS/EEG), test chronic protocols, and match outcomes to what the PFC actually influences (pacing decisions, inhibition, interoception). - Episode timeline 0:19–1:42 — The promise vs the test: trained cyclists + double-blind crossover; headline null result 1:59–3:27 — Why tPBM could work: mitochondria, CC

Can photobiomodulation (red + near-infrared light) meaningfully improve glycemic control in people with type 2 diabetes? In this Deep Dive, Dr. Mike Belkowski breaks down a 2026 systematic review of randomized clinical trials that tested PBM for diabetes outcomes like fasting glucose, post-prandial glucose, and HbA1c. The evidence base is small — only 4 RCTs met strict inclusion criteria (control/sham required) — but the signal was generally favorable: PBM was associated with reductions in fasting glucose, post-prandial glucose, and HbA1c, and in some studies improvements in lipid markers. The catch is that overall certainty is very low to low due to small samples, protocol heterogeneity, and bias concerns. Translation: promising adjunct, not proven therapy, and not remotely a replacement for standard care. (Educational content only, not medical advice.) - Article Discussed in Episode: Photobiomodulation Therapy to Improve Glycemic Control in People with Diabetes Mellitus: A Systematic Review - Key Quotes From Dr. Mike: “Type 2 diabetes… chronic hyperglycemia disrupts mitochondrial metabolism, increases oxidative stress, activates inflammatory pathways…” “PBM, mostly red and near infrared wavelengths, was associated with reductions in fasting glucose, postprandial glucose, and HBA1C.” “These were longer protocols, 30 minutes per session, 3 sessions per week for 12 weeks.” “PBM is not a replacement for medication, nutrition, exercise, or medical monitoring.” “We’re early, but the direction is real.” - Key Points The review included 4 randomized clinical trials (1993–2025 search; control/sham required). Outcomes emphasized fasting glucose, post-prandial glucose, HbA1c, plus some cardiometabolic measures. Overall finding: PBM was generally associated with improved glycemic markers, sometimes lipids too. Evidence certainty: very low to low (small N, heterogeneity, some risk-of-bias concerns). Protocol types: Wrist “watch” PBM over radial pulse area: 30 min, 3x/week, 12 weeks, often alongside meds. LED pad PBM over large tissue regions (limbs/abdomen): crossover, sham-controlled, acute/time-response.   Dose response looks biphasic (a “sweet spot”): one trial found 100 J sustained lower glycemia up to 12 hours, while higher dose wasn’t clearly better.

Most conversations about Alzheimer’s and mitochondria stay in broad strokes. This Deep Dive episode doesn’t. Dr. Mike Belkowski breaks down a study that examined postmortem human brain tissue to answer a precise question: do mitochondrial electron transport chain proteins shift in Alzheimer’s the same way they shift in normal aging — or is Alzheimer’s a different mitochondrial pattern entirely? Using three groups (young controls 35–45, aged controls >85 without Alzheimer’s pathology, and sporadic Alzheimer’s cases 85–89), the researchers measured neuron-level immunohistochemical intensity (a proxy for relative protein abundance) for key mitochondrial markers: complex IV subunits MTCO1/MTCO2, complex V (ATP synthase), and IF1, the ATP synthase inhibitory factor that helps prevent catastrophic ATP “backwards burning” during stress and supports crista integrity. The core finding: Alzheimer’s shows electron transport chain instability that differs from physiological aging, and the hippocampus (CA1/CA2) stands out as a failure zone — losing IF1 and failing to mount the compensatory ATP synthase response seen in other regions. In Energy Code terms: memory circuits are energy-expensive, and Alzheimer’s appears to remove mitochondrial protection exactly where it’s needed most. (Educational content only, not medical advice.) - Article Discussed in Episode: Immunohistochemical Markers of Mitochondrial Electron Transport Chain Instability in Human Brain Regions: A Study of Aging and Alzheimer’s Disease - Key Quotes From Dr. Mike: “Do the mitochondrial electron transport chain proteins change in Alzheimer’s… or is Alzheimer’s a fundamentally different mitochondrial pattern?” “Alzheimer’s shows a pattern of mitochondrial electron transport chain instability that is fundamentally distinct from physiological aging.” “The hippocampus appears to be uniquely vulnerable because it fails to mount a protective compensatory response.” “Alzheimer’s shows instability, and the hippocampus stands out as a failure zone.” “Memory circuits depend on mitochondrial resilience… and the hippocampus loses mitochondrial protection exactly where it needs it most.” - Key Points The study compares young controls, aged controls, and sporadic Alzheimer’s using human brain tissue. Multiple regions were analyzed: middle frontal gyrus, anterior cingulate, caudate, hippocampus CA1/CA2, inferior parietal lobule. Markers measured (IHC intensity proxy): MTCO1 + MTCO2 (complex IV), complex V (ATP synthase m

Mitophagy is the body’s targeted mitochondrial cleanup system; not general autophagy, but the precise identification and removal of damaged mitochondria so cells can recycle parts and rebuild stronger. In this Deep Dive, Dr. Mike Belkowski breaks down a newly published review, “Mitophagy in the Pathogenesis and Management of Disease,” and explains why mitophagy is more than housekeeping — it’s a strategic control system for mitochondrial integrity, metabolic balance, redox signaling, and immune tone. You’ll learn the two major mitophagy “toolkits” (ubiquitin-mediated PINK1/Parkin and receptor-mediated pathways like BNIP3/NIX/FUNDC1), why basal mitophagy doesn’t always depend on PINK1/Parkin, how lipids like cardiolipin can act as mitophagy signals, and why “piecemeal mitophagy” may preserve mitochondria without scrapping the whole organelle. Then the episode maps how mitophagy dysregulation shows up across neurodegeneration, immune dysfunction, metabolic disease, cardiovascular disease, and cancer — where mitophagy can be both tumor-suppressive and tumor-supportive depending on context. Finally, it closes with the therapeutic frontier: precision mitophagy medicine (i.e., right pathway, right tissue, right timing, right intensity). (Educational content only, not medical advice.) - Article Discussed in Episode: Mitophagy in the pathogenesis and management of disease - Key Quotes From Dr. Mike: “Mitophagy is the targeted removal of damaged mitochondria.” “When mitophagy works, you maintain mitochondrial quality.” “When mitophagy fails or becomes dysregulated… oxidative stress rises, inflammation gets louder.” “The goal is not maximum mitophagy, the goal is appropriate mitophagy.” “Urolithin A is the only clinically validated bioactive compound shown to enhance mitophagy in humans so far.” - Key Points Mitophagy = targeted removal of damaged mitochondria (not general autophagy). It’s a control system for mitochondrial integrity, redox balance, immune tone, and metabolic resilience. Mitochondria require coordination between mtDNA + nuclear DNA; mitonuclear imbalance drives proteotoxic stress. Quality control layers: biogenesis, fusion/fission, proteostasis/UPRmt, MDVs—mitophagy is the bulk disposal pathway. Two main signaling routes: Ubiquitin-mediated: PINK1 → phosphorylated ubiquitin → Parkin → ubiquitin coat → OPTN/NDP52 → autophagosome → lysosome. Receptor-m